CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
10517337,105173374,4,F,,20170313,20141014,20170320,EXP,,CA-ABBVIE-14P-028-1294092-00,ABBVIE,,54,YR,,M,Y,,,20170320,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,105173374,OT,,,,,,,,,105173374,1,Product used for unknown indication
11116909,111169095,5,F,20141031,20161227,20150515,20170103,EXP,,UG-GILEAD-2014-0123355,GILEAD,,36,YR,A,M,Y,56,KG,20170103,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abdominal pain upper;Aspartate aminotransferase increased;Pancreatitis;Thrombocytopenia;Vomiting,111169095,OT,,,111169095,1,20140328,20141117,,,111169095,1,HIV infection
11307801,1130780112,12,F,,20170320,20150724,20170329,EXP,,DE-ROCHE-1495718,ROCHE,", WELZEL T, SPENGLER U, HINRICHSEN H, UMGELTER A, GRUNER N, KLASS D, WIEGAND J AND ZIMMERMANN T. SAFETY AND EFFICACY OF DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN FOR HEPATITIS C POST-TRANSPLANT: INTERIM RESULTS FROM THE COMPASSIONATE USE PROGRAM [ABSTRACT NUMBER: P070].. TRANSPLANT INTERNATIONAL 2015;28 (SUP2):35-.",,,,,Y,,,20170329,,MD,DE,DE,EFAVIRENZ,Abdominal pain;Acute kidney injury;Anaemia;Anal cancer;Arthralgia;Blood creatinine increased;Calculus urinary;Circulatory collapse;Clostridium difficile colitis;Dehydration;Dermatitis allergic;Diarrhoea;Drug withdrawal syndrome;Dyspnoea;Erysipelas;Fatigue;Fluid overload;Gastrointestinal disorder;Gastrointestinal infection;General physical health deterioration;Haemorrhoidal haemorrhage;Headache;Hepatic encephalopathy;Hepatic failure;Hepatobiliary disease;Hepatocellular carcinoma;Hypersensitivity vasculitis;Hypertension;Hyponatraemia;Infection;Lactic acidosis;Liver disorder;Lymphoedema;Mental disorder;Myocardial infarction;Nausea;Neoplasm;Neutropenia;Pancreatitis acute;Pancytopenia;Peritonitis bacterial;Portal vein thrombosis;Sleep disorder;Soft tissue infection;Somnolence;Streptococcal sepsis;Vertigo,1130780112,OT,,,,,,,,,1130780112,1,Chronic hepatitis C
11316440,113164402,2,F,,20170215,20150728,20170222,EXP,,CA-ABBVIE-15P-028-1431693-00,ABBVIE,,,,,M,Y,,,20170222,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,113164402,OT,,,,,,,,,113164402,1,Product used for unknown indication
11318133,113181333,3,F,,20170313,20150728,20170320,EXP,,CA-ABBVIE-15P-028-1431684-00,ABBVIE,,54,YR,,M,Y,,,20170320,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,113181333,OT,,,,,,,,,113181333,1,Product used for unknown indication
11318157,113181573,3,F,,20170313,20150728,20170320,EXP,,CA-ABBVIE-15P-028-1431692-00,ABBVIE,,54,YR,,M,Y,,,20170320,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,113181573,OT,,,,,,,,,113181573,1,Product used for unknown indication
11318178,113181783,3,F,,20170313,20150728,20170320,EXP,,CA-ABBVIE-15P-028-1431123-00,ABBVIE,,54,YR,,M,Y,,,20170320,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,113181783,OT,,,,,,,,,113181783,1,Product used for unknown indication
11362483,113624833,3,F,20141011,20170105,20150810,20170110,EXP,,ZW-GILEAD-2015-0156068,GILEAD,,30,YR,A,F,Y,,,20170110,,OT,ZW,ZW,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,113624833,OT,,,113624833,1,20140619,20150520,,,113624833,1,HIV infection
11775819,117758192,2,F,2012,20161202,20151125,20170116,PER,,US-JNJFOC-20151105205,JANSSEN,,,,A,M,Y,,,20170116,,CN,US,US,SUSTIVA,Abnormal weight gain;Gynaecomastia,117758192,OT,,,117758192,1,2008,2012,,,117758192,1,Schizophrenia
11937618,119376183,3,F,,20170117,20160122,20170130,EXP,,CA-009507513-1601CAN007640,MERCK,,,,,M,Y,,,20170130,,CN,US,CA,SUSTIVA,Depression;Drug interaction,119376183,OT,,,,,,,,,119376183,1,Product used for unknown indication
12378500,123785005,5,F,20160426,20170109,20160517,20170113,EXP,,MZ-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-037701,BRISTOL MYERS SQUIBB,,40,YR,,F,Y,50,KG,20170113,,OT,MZ,MZ,EFAVIRENZ,Back pain;Drug eruption;Gastroenteritis;Transaminases increased,123785005,HO,,,123785005,1,20160418,20160508,,,123785005,1,HIV infection
12455220,124552203,3,F,20160314,20161229,20160610,20170103,EXP,,ZA-JNJFOC-20160601626,JANSSEN,,55,YR,A,M,Y,56.2,KG,20170103,,MD,ZA,ZA,EFAVIRENZ W/EMTRICITABINE/TENOFOVIR DISOPROXI,Diarrhoea;Electrocardiogram QT prolonged;Tinnitus;Vomiting,124552203,OT,,,124552203,1,20160310,20160316,,,124552203,1,Tuberculosis
12550531,125505312,2,F,,20170119,20160712,20170125,EXP,,CA-ABBVIE-16P-028-1672373-00,ABBVIE,,,,,M,Y,,,20170125,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,125505312,OT,,,,,,,,,125505312,1,Product used for unknown indication
12567182,125671825,5,F,20160603,20170316,20160718,20170322,EXP,,FR-GILEAD-2016-0223323,GILEAD,,33,YR,A,M,Y,68,KG,20170322,,CN,FR,FR,EFAVIRENZ;SUSTIVA,Atrial flutter;Cardiac failure;Hepatocellular injury;Myocarditis;Renal impairment;Transplant rejection,125671825,HO,,,125671825,1,20160405,20160628,,,125671825,1,Chronic hepatitis C
12629480,126294804,4,F,,20170116,20160808,20170116,EXP,,IL-VIIV HEALTHCARE LIMITED-IL2016GSK112580,VIIV,"MAHLAB-GURI K, ASHER I, ROSENBERG-BEZALEL S, ELBIRT D, BURKE M, STHOEGER ZM. TWO CASE REPORTS OF SEVERE MYOCARDITIS ASSOCIATED WITH THE INITIATION OF DOLUTEGRAVIR TREATMENT IN HIV PATIENTS. MEDICINE. 2016;95:47",45,YR,,F,Y,,,20170116,,MD,IL,IL,Efavirenz,Aspartate aminotransferase increased;Blood creatine phosphokinase increased;Cardiac failure;Depression;Diarrhoea;Dyspnoea;Left ventricular dysfunction;Myocarditis;Necrosis;Oedema peripheral;Pyrexia;Troponin T increased,126294804,OT,,,,,,,,,126294804,1,HIV infection
12643972,126439724,4,F,,20170116,20160811,20170116,EXP,,IL-VIIV HEALTHCARE LIMITED-IL2016GSK112581,VIIV,"MAHLAB-GURI K, ASHER I, ROSENBERG-BEZALEL S, ELBIRT D, BURKE M, STHOEGER ZM. TWO CASE REPORTS OF SEVERE MYOCARDITIS ASSOCIATED WITH THE INITIATION OF DOLUTEGRAVIR TREATMENT IN HIV PATIENTS. MEDICINE. 2016;95:47",51,YR,,M,Y,,,20170116,,MD,IL,IL,Efavirenz,Aspartate aminotransferase increased;Blood lactate dehydrogenase increased;Cardiac failure;Coronary artery stenosis;Dyspnoea;Ischaemic stroke;Myocarditis;Oedema peripheral;Sleep disorder;Troponin T increased;Ventricular dysfunction,126439724,OT,,,,,,,,,126439724,1,HIV infection
12689615,1268961514,14,F,20160812,20170321,20160826,20170324,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2016GSK123261,VIIV,,37,YR,,F,Y,43,KG,20170324,,MD,BR,BR,EFAVIRENZ,Acute kidney injury;Immune reconstitution inflammatory syndrome,1268961514,OT,,,1268961514,1,20160805,20160819,,,1268961514,1,HIV infection
12755348,127553482,2,F,,20170126,20160916,20170206,EXP,,PHHY2016US127187,SANDOZ,"LAZENBY GB, MMEJE O, FISHER BM, WEINBERG A, AARON EK, KEATING M, ET AL.. ANTIRETROVIRAL RESISTANCE AND PREGNANCY CHARACTERISTICS OF WOMEN WITH PERINATAL AND NONPERINATAL HIV INFECTION.. INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY. 2016",,,,F,Y,,,20170206,,OT,US,US,EFAVIRENZ,Drug resistance;Maternal exposure during pregnancy,127553482,OT,,,,,,,,,127553482,1,Perinatal HIV infection
12756064,127560642,2,F,,20170215,20160916,20170228,EXP,,GB-MYLANLABS-2016M1039688,MYLAN,"GRIMES R, APPLEBY T, STOCKWELL S, SANDER NP, SAHABANDU T, GILLEECE Y, BRADSHAW D, STEIN P. A CASE OF HEREDITARY COPROPORPHYRIA TRIGGERED BY EFAVIRENZ. HIV MEDICINE 17 (SUPPL. 1): 53 ABSTR. P119, APR 2016.",,,,,Y,,,20170228,,OT,GB,GB,EFAVIRENZ,Porphyria acute,127560642,OT,,,,,,,,,127560642,1,Antiretroviral therapy
12781371,127813716,6,F,20160901,20170117,20160926,20170125,EXP,,US-ACTELION-A-US2016-142509,ACTELION,,58,YR,A,M,Y,,,20170125,,MD,US,US,SUSTIVA,Abdominal pain;Alanine aminotransferase increased;Ascites;Aspartate aminotransferase increased;Blood alkaline phosphatase increased;Blood bilirubin increased;Cardiac failure;Chills;Cholecystitis;Cholelithiasis;Chromaturia;Feeling abnormal;Hepatic pain;Hyponatraemia;International normalised ratio increased;Jaundice;Liver function test abnormal;Nausea;Portal vein pressure increased;Pyrexia,127813716,HO,,,127813716,1,20160319,,,,127813716,1,Pulmonary arterial hypertension
12786689,127866893,3,F,20160828,20170203,20160927,20170210,EXP,,MW-GILEAD-2016-0233550,GILEAD,,50,YR,A,M,Y,41.7,KG,20170210,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE;TENOFOVIR + LAMIVUDINE + EFAVIRENZ,Pulmonary tuberculosis,127866893,HO,,,127866893,1,20160816,20160816,,,127866893,1,Kaposi's sarcoma AIDS related
12792737,127927372,2,F,201606,20170111,20160929,20170117,PER,,US-JAZZ-2016-US-011546,JAZZ,,57,YR,,M,Y,,,20170117,,,US,US,Efavirenz,Hunger;Hypertension;Thirst,,,,,127927372,1,201507,201507,,,127927372,1,Narcolepsy
12804079,128040793,3,F,20120415,20170217,20161003,20170301,EXP,,UG-GILEAD-2014-0093655,GILEAD,,33,YR,A,F,Y,38,KG,20170301,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Burning sensation;Diarrhoea;Hypokalaemia;Hyponatraemia;Malaise;Muscular weakness;Oedema peripheral;Pyrexia;Skin hyperpigmentation;Vomiting,128040793,HO,,,128040793,1,20121114,20140122,,,128040793,1,HIV infection
12808470,128084703,3,F,20160909,20170223,20161004,20170228,EXP,,PE-GILEAD-2016-0235852,GILEAD,,39,YR,A,F,Y,54,KG,20170228,,MD,PE,PE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Major depression,128084703,OT,,,128084703,1,20160106,,,,128084703,1,HIV infection
12855273,128552733,3,F,20161003,20170216,20161017,20170227,EXP,,MW-GILEAD-2016-0237668,GILEAD,,25,YR,A,M,Y,,,20170227,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bacterial sepsis,128552733,HO,,,128552733,1,20160818,,,,128552733,1,Acquired immunodeficiency syndrome
12867329,128673292,2,F,,20170111,20161020,20170117,EXP,,GB-GILEAD-2016-0238371,GILEAD,,,,,M,Y,,,20170117,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Amnesia,,,,,,,,,,,128673292,1,Product used for unknown indication
12991976,129919762,2,F,,20170103,20161201,20170111,EXP,,TR-GILEAD-2016-0245947,GILEAD,,44,YR,A,M,Y,,,20170111,,MD,TR,TR,EFAVIRENZ,Anogenital dysplasia,129919762,OT,,,,,,,,,129919762,1,HIV infection
12996569,129965695,5,F,201612,20170127,20161204,20170202,EXP,,CA-GLAXOSMITHKLINE-CA2016GSK157626,GLAXOSMITHKLINE,,49,YR,,M,Y,,,20170202,,CN,CA,CA,Efavirenz,Aphonia;Dysphonia;Eczema;Hepatitis B;Intervertebral disc protrusion;Lumbar spinal stenosis;Nasopharyngitis;Nausea;Pulmonary pain;Sleep disorder;Syphilis,129965695,OT,,,129965695,2,20161025,,,,129965695,1,Product used for unknown indication
12999963,129999633,3,F,20160930,20170120,20161205,20170130,EXP,,PE-GILEAD-2016-0245926,GILEAD,,55,YR,A,M,Y,71,KG,20170130,,MD,PE,PE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Intervertebral disc protrusion,129999633,HO,,,129999633,1,20160210,,,,129999633,1,HIV infection
13007600,130076004,4,F,2011,20170227,20161207,20170302,EXP,,FR-GILEAD-2016-0247270,GILEAD,,60,YR,A,M,Y,72,KG,20170302,,PH,FR,FR,SUSTIVA,Hepatic cancer;Hepatitis B DNA assay positive;Nephropathy toxic;Off label use;Overdose;Renal failure;Virologic failure,130076004,OT,,,130076004,1,20021215,201105,,,130076004,1,Hepatitis B
13014538,130145383,3,F,,20170203,20161209,20170209,EXP,,PHHY2015BR064616,NOVARTIS,,,,,F,Y,49.98,KG,20170209,,MD,BR,BR,EFAVIRENZ,Alopecia;Blood iron increased;Chills;Dizziness;Drug intolerance;Haemoglobin abnormal;Inappropriate schedule of drug administration;Malaise;Nausea;Poisoning;Serum ferritin abnormal;Serum ferritin decreased;Serum ferritin increased;Vomiting;Weight increased;Wrong technique in product usage process,130145383,OT,,,,,,,,,130145383,1,Haemoglobinopathy
13018663,130186633,3,F,20161123,20170104,20161212,20170105,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-105613,BRISTOL MYERS SQUIBB,,33,YR,,M,Y,53.3,KG,20170105,,OT,MW,MW,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Anaemia;Kaposi's sarcoma;Thrombocytopenia,130186633,DE,,,130186633,1,20151027,,,,130186633,1,HIV infection
13029717,130297172,2,F,,20170104,20161215,20170110,EXP,,GB-ASTELLAS-2016US048617,ASTELLAS,,47,YR,,M,Y,,,20170110,,MD,GB,GB,EFAVIRENZ,HIV infection;Hepatic cirrhosis,130297172,OT,,,130297172,1,20110716,,,,130297172,1,Liver transplant
13037962,130379622,2,F,20160422,20170113,20161218,20170117,EXP,,MZ-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-107358,BRISTOL MYERS SQUIBB,,31,YR,,F,Y,41,KG,20170117,,OT,MZ,MZ,EFAVIRENZ,Anaemia;Pneumonia bacterial,130379622,OT,,,130379622,1,20160415,,,,130379622,1,HIV infection
13059080,130590803,3,F,20160111,20170130,20161223,20170202,EXP,,UG-GILEAD-2016-0250168,GILEAD,,28,YR,A,F,Y,53,KG,20170202,,MD,UG,UG,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,130590803,OT,,,130590803,1,20140113,,,,130590803,1,HIV infection
13067439,130674392,2,F,20160729,20170120,20161228,20170202,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-109185,BRISTOL MYERS SQUIBB,,34,YR,,F,Y,,,20170202,,CN,BR,BR,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy;Product use issue,130674392,OT,,,130674392,1,20160610,,,,130674392,1,HIV infection
13077160,130771602,2,F,20161123,20170104,20161230,20170111,EXP,,MW-GILEAD-2016-0248704,GILEAD,,33,YR,A,M,Y,53.3,KG,20170111,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Kaposi's sarcoma;Thrombocytopenia,130771602,OT,,,130771602,1,20151027,20161206,,,130771602,1,Kaposi's sarcoma AIDS related
13078605,130786051,1,I,,20161219,20170102,20170102,EXP,,"ES-NOVEL LABORATORIES, INC-2017-00025",NOVEL LABS,"MEDRANO-CASIQUE N, TONG H, BOROBIA A, CARCAS A, FRIAS J, RAMIREZ E. NON-CHEMOTHERAPY-INDUCED AGRANULOCYTOSIS DETECTED BY A PROSPECTIVE PHARMACOVIGILANCE PROGRAM IN A TERTIARY HOSPITAL. BASIC + CLINICAL PHARMACOLOGY + TOXICOLOGY. 2015;117:399-408.",47,YR,,M,Y,,,20170102,,OT,ES,ES,EMTRICITABIN / TENOFOVIR DISOPROXIL / EFAVIRENZ,Agranulocytosis,130786051,DE,,,,,,,,,130786051,1,Pneumonia
13079073,130790731,1,I,,20161221,20170102,20170102,EXP,,GB-MYLANLABS-2016M1058108,MYLAN,,,,,,Y,,,20161228,,CN,GB,GB,EFAVIRENZ,Chronic obstructive pulmonary disease,130790731,HO,,,,,,,,,130790731,1,Product used for unknown indication
13081932,130819321,1,I,201612,20140915,20170103,20170103,EXP,,PHHY2014IN119925,NOVARTIS,,52,YR,,M,Y,,,20170103,,CN,IN,IN,EFAVIRENZ,Drug level decreased;Fall;Hand fracture;Osteoporosis;Therapy non-responder;Varicella,130819321,OT,,,,,,,,,130819321,1,Chronic myeloid leukaemia
13083194,130831943,3,F,,20170118,20170104,20170118,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-112414,BRISTOL MYERS SQUIBB,,,,N,F,Y,2.8,KG,20170118,,OT,NG,NG,EFAVIRENZ,Cleft palate;Foetal exposure during pregnancy,130831943,OT,,,,,,,,,130831943,1,Product used for unknown indication
13083246,130832463,3,F,,20170118,20170104,20170118,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-112415,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,,,20170118,,OT,NG,NG,EFAVIRENZ,Maternal exposure during pregnancy;Premature delivery;Product use issue;Pyrexia,130832463,OT,,,,,,,,,130832463,1,HIV infection
13083247,130832473,3,F,,20170118,20170104,20170118,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-112416,BRISTOL MYERS SQUIBB,,1,DY,,M,Y,2.8,KG,20170118,,OT,NG,NG,EFAVIRENZ,Cleft palate;Foetal exposure during pregnancy;Hypoacusis;Premature baby,130832473,CA,,,,,,,,,130832473,1,Product used for unknown indication
13083427,130834271,1,I,,20161202,20170104,20170104,PER,,JP-LUPIN PHARMACEUTICALS INC.-2016-05494,LUPIN,"UEHARA Y, SUZUKI A, SAITA M, INUI A, ISONUMA H, NAITO T. RALTEGRAVIR AND ABACAVIR/LAMIVUDINE IN JAPANESE TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH HIV INFECTION: A 48-WEEK RETROSPECTIVE PILOT ANALYSIS.. JAPANESE JOURNAL OF INFECTIOUS DISEASES. 2016;69(1):33-38.",40,YR,,M,Y,,,20170104,,OT,JP,JP,Efavirenz,Insomnia,,,,,,,,,,,130834271,1,HIV infection
13084952,130849521,1,I,2015,20151215,20170104,20170104,EXP,,US-BMSGILMSD-2015-0188646,GILEAD,,68,YR,E,M,Y,,,20170104,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death;Dyspnoea,130849521,DE,,,,,,,,,130849521,1,HIV infection
13085241,130852411,1,I,,20161228,20170104,20170104,EXP,,US-GILEAD-2016-0251353,GILEAD,,45,YR,A,M,Y,,,20170104,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Neoplasm,130852411,OT,,,,,,,,,130852411,1,HIV infection
13085644,130856441,1,I,,20161228,20170104,20170104,EXP,,IT-ABBVIE-17P-083-1827452-00,ABBVIE,"BARONCELLI Z, MICHELINI Z, GALLUZZO C, ET AL. HIV-1 DNA DYNAMICS AND VARIATIONS IN HIV-1 DNA PROTEASE AND REVERSE TRANSCRIPTASE SEQUENCES IN MULTIDRUG RESISTANT PATIENTS DURING SUCCESSFUL RALTEGRAVIR-BASED THERAPY.. JOURNAL OF MEDICAL VIROLOGY. 2016;2115-2124.",45,YR,,,Y,,,20170104,,MD,COUNTRY NOT SPECIFIED,IT,EFAVIRENZ,Drug resistance;Viral mutation identified,130856441,OT,,,,,,,,,130856441,1,HIV infection
13085666,130856661,1,I,,20161228,20170104,20170104,EXP,,IT-ABBVIE-17P-083-1827457-00,ABBVIE,"BARONCELLI S, MICHELINI Z, GALLUZZO C, ET AL. HIV-1 DNA DYNAMIC AND VARIATIONS IN HIV-1 DNA PROTEASE AND REVERSE TRANSCRIPTASE SEQUENCES IN MULTIDRUG RESISTANT PATIENTS DURING SUCCESSFUL RALTEGRAVIR-BASED THERAPY. JOURNAL OF MEDICAL VIROLOGY. 2016;2115-2124.",45,YR,,,Y,,,20170104,,MD,COUNTRY NOT SPECIFIED,IT,EFAVIRENZ,Drug resistance;Viral mutation identified,130856661,OT,,,,,,,,,130856661,1,HIV infection
13086191,130861911,1,I,201412,20161227,20170104,20170104,EXP,,US-GILEAD-2016-0251329,GILEAD,,59,YR,A,M,Y,,,20170104,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Influenza,130861911,HO,,,130861911,1,2013,,,,130861911,1,HIV infection
13090025,130900251,1,I,,20161226,20170105,20170105,EXP,,DE-VIIV HEALTHCARE LIMITED-DE2016GSK195552,VIIV,"KROIDL A, MGAYA J, LENEMANN T, MOH R, MAGANGA L, EHOLIE S ET AL.. VIROLOGICAL EFFICACY OF 24-WEEKS FOZIVUDINE BASED REGIMEN IN ART-NAIVE PATIENTS FROM TANZANIA AND COTE D^IVOIRE. 2016",,,,,Y,,,20170105,,MD,DE,DE,Efavirenz,Virologic failure,130900251,OT,,,,,,,,,130900251,1,HIV infection
13090070,130900701,1,I,,20161226,20170105,20170105,EXP,,DE-GLAXOSMITHKLINE-DE2016GSK195552,GLAXOSMITHKLINE,"KROIDL A, MGAYA J, LENEMANN T, MOH R, MAGANGA L, EHOLIE S ET AL.. VIROLOGICAL EFFICACY OF 24-WEEKS FOZIVUDINE BASED REGIMEN IN ART-NAIVE PATIENTS FROM TANZANIA AND COTE D^IVOIRE. 2016",,,,,Y,,,20170105,,MD,DE,DE,Efavirenz,Virologic failure,130900701,OT,,,,,,,,,130900701,1,HIV infection
13090102,130901021,1,I,,20161228,20170105,20170105,EXP,,IT-GILEAD-2017-0251961,GILEAD,,,,A,,Y,,,20170105,,MD,IT,IT,EFAVIRENZ,Drug resistance;Viral mutation identified,130901021,OT,,,,,,,,,130901021,1,HIV infection
13090527,130905271,1,I,,20170104,20170105,20170105,EXP,,GB-GILEAD-2017-0252099,GILEAD,,43,YR,A,M,Y,,,20170105,,PH,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,130905271,DE,,,,,,,,,130905271,1,Product used for unknown indication
13090798,130907983,3,F,20160629,20170207,20170106,20170213,EXP,,CI-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-056226,BRISTOL MYERS SQUIBB,,26,YR,,M,Y,51,KG,20170213,,MD,CI,CI,EFAVIRENZ,Encephalopathy;General physical condition abnormal;Hepatic enzyme increased;Hepatocellular injury,130907983,DE,,,130907983,1,20160511,20161228,,,130907983,1,HIV infection
13091875,130918751,1,I,,20161230,20170106,20170106,EXP,,US-BAYER-2017-000035,BAYER,,,,,,Y,,,20170106,,CN,US,US,SUSTIVA,Cerebrovascular accident,130918751,OT,,,,,,,,,130918751,1,Gastrointestinal stromal cancer
13093353,130933531,1,I,,20161228,20170106,20170106,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2016195662,VIIV,"MICHELINI Z., ET AL. HIV-1 DNA DYNAMICS AND VARIATIONS IN HIV-1 DNA PROTEASE AND REVERSE TRANSCRIPTASE SEQUENCES IN MULTIDRUG RESISTANT PATIENTS DURING SUCCESSFUL RALTEGRAVIR-BASED THERAPY.. JOURNAL OF MEDICAL VIROLOGY. 2016;88:12:2115-2124",,,A,,Y,,,20170106,,MD,IT,IT,Efavirenz,Drug resistance;Viral mutation identified,130933531,OT,,,,,,,,,130933531,1,HIV infection
13093355,130933551,1,I,,20161228,20170106,20170106,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2016195654,VIIV,,,,A,,Y,,,20170106,,MD,IT,IT,Efavirenz,Drug resistance;Viral mutation identified,130933551,OT,,,,,,,,,130933551,1,HIV infection
13093366,130933661,1,I,,20161228,20170106,20170106,EXP,,IT-GLAXOSMITHKLINE-IT2016195654,GLAXOSMITHKLINE,,,,A,,Y,,,20170106,,MD,IT,IT,Efavirenz,Drug resistance;Viral mutation identified,130933661,OT,,,,,,,,,130933661,1,HIV infection
13093372,130933721,1,I,,20161228,20170106,20170106,EXP,,IT-GLAXOSMITHKLINE-IT2016195662,GLAXOSMITHKLINE,"MICHELINI Z., ET AL. HIV-1 DNA DYNAMICS AND VARIATIONS IN HIV-1 DNA PROTEASE AND REVERSE TRANSCRIPTASE SEQUENCES IN MULTIDRUG RESISTANT PATIENTS DURING SUCCESSFUL RALTEGRAVIR-BASED THERAPY.. JOURNAL OF MEDICAL VIROLOGY. 2016;88:12:2115-2124",,,A,,Y,,,20170106,,MD,IT,IT,Efavirenz,Drug resistance;Viral mutation identified,130933721,OT,,,,,,,,,130933721,1,HIV infection
13094456,130944561,1,I,,20161228,20170106,20170106,EXP,IT-MINISAL02-389982,IT-MYLANLABS-2017M1000023,MYLAN,MICHELINI Z.. HIV-1 DNA DYNAMIC AND VARIATIONS IN HIV-1 DNA PROTEASE AND REVERSE TRANSCRIPTASE SEQUENCES IN MULTIDRUG RESISTANT PATIENTS DURING SUCCESSFUL RALTEGRAVIR-BASED THERAPY. JOURNAL OF MEDICAL VIROLOGY,,,,,Y,,,20170106,,OT,IT,IT,EFAVIRENZ,Drug resistance;Viral mutation identified,130944561,OT,,,,,,,,,130944561,1,HIV infection
13094483,130944831,1,I,,20161228,20170106,20170106,EXP,IT-MINISAL02-390000,IT-MYLANLABS-2017M1000021,MYLAN,MICHELINI Z. HIV-1 DNA DYNAMICS AND VARIATIONS IN HIV-1 DNA PROTEASE AND REVERSE TRANSCRIPTASE SEQUENCES IN MULTIDRUG RESISTANT PATIENTS DURING SUCCESSFUL RALTEGRAVIR-BASED THERAPY. JOURNAL OF MEDICAL VIROLOGY,,,,,Y,,,20170106,,OT,IT,IT,EFAVIRENZ,Drug resistance;Viral mutation identified,130944831,OT,,,,,,,,,130944831,1,HIV infection
13095809,130958091,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00084,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130958091,DE,,,130958091,1,2009,,,,130958091,1,HIV infection
13095900,130959001,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00091,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130959001,DE,,,130959001,1,2010,,,,130959001,1,HIV infection
13095907,130959071,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00093,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130959071,DE,,,130959071,1,2011,,,,130959071,1,HIV infection
13095923,130959231,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00092,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130959231,DE,,,130959231,1,2010,,,,130959231,1,HIV infection
13095928,130959281,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00090,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130959281,DE,,,130959281,1,2009,,,,130959281,1,HIV infection
13095936,130959361,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00089,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130959361,DE,,,130959361,1,2009,,,,130959361,1,HIV infection
13095944,130959441,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00088,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130959441,DE,,,130959441,1,2010,,,,130959441,1,HIV infection
13095957,130959571,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00087,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130959571,DE,,,130959571,1,2009,,,,130959571,1,HIV infection
13095992,130959921,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00086,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130959921,DE,,,130959921,1,2009,,,,130959921,1,HIV infection
13096030,130960301,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00085,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130960301,DE,,,130960301,1,2010,,,,130960301,1,HIV infection
13096043,130960431,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00104,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130960431,DE,,,130960431,1,2011,,,,130960431,1,HIV infection
13096061,130960611,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00103,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130960611,DE,,,130960611,1,2011,,,,130960611,1,HIV infection
13096075,130960751,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00101,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130960751,DE,,,130960751,1,2010,,,,130960751,1,HIV infection
13096078,130960781,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00102,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130960781,DE,,,130960781,1,2010,,,,130960781,1,HIV infection
13096084,130960841,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00100,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130960841,DE,,,130960841,1,2009,,,,130960841,1,HIV infection
13096090,130960901,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00099,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130960901,DE,,,130960901,1,2010,,,,130960901,1,HIV infection
13096097,130960971,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00098,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130960971,DE,,,130960971,1,2012,,,,130960971,1,HIV infection
13096100,130961001,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00097,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130961001,DE,,,130961001,1,2010,,,,130961001,1,HIV infection
13096103,130961031,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00096,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130961031,DE,,,130961031,1,2009,,,,130961031,1,HIV infection
13096111,130961111,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00095,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130961111,DE,,,130961111,1,2009,,,,130961111,1,HIV infection
13096114,130961141,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00094,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130961141,DE,,,130961141,1,2009,,,,130961141,1,HIV infection
13096136,130961361,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00145,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Virologic failure,130961361,OT,,,130961361,1,2011,,,,130961361,1,HIV infection
13096155,130961551,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00112,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130961551,DE,,,130961551,1,2011,,,,130961551,1,HIV infection
13096157,130961571,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00110,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130961571,DE,,,130961571,1,2009,,,,130961571,1,HIV infection
13096161,130961611,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00111,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130961611,DE,,,130961611,1,2011,,,,130961611,1,HIV infection
13096183,130961831,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00109,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130961831,DE,,,130961831,1,2010,,,,130961831,1,HIV infection
13096200,130962001,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00108,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130962001,DE,,,130962001,1,2009,,,,130962001,1,HIV infection
13096201,130962011,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00107,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130962011,DE,,,130962011,1,2009,,,,130962011,1,HIV infection
13096208,130962081,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00106,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130962081,DE,,,130962081,1,2009,,,,130962081,1,HIV infection
13096212,130962121,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00146,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Virologic failure,130962121,OT,,,130962121,1,2011,,,,130962121,1,HIV infection
13096214,130962141,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00147,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Virologic failure,130962141,OT,,,130962141,1,2012,,,,130962141,1,HIV infection
13096222,130962221,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00149,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130962221,DE,,,130962221,1,2009,,,,130962221,1,HIV infection
13096319,130963191,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00150,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130963191,DE,,,130963191,1,2009,,,,130963191,1,HIV infection
13096326,130963261,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00151,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130963261,DE,,,130963261,1,2009,,,,130963261,1,HIV infection
13096343,130963431,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00152,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130963431,DE,,,130963431,1,2010,,,,130963431,1,HIV infection
13096347,130963471,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00153,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130963471,DE,,,130963471,1,2011,,,,130963471,1,HIV infection
13096352,130963521,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00154,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130963521,DE,,,130963521,1,2009,,,,130963521,1,HIV infection
13096366,130963661,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00155,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130963661,DE,,,130963661,1,2010,,,,130963661,1,HIV infection
13096380,130963801,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00156,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130963801,DE,,,130963801,1,2011,,,,130963801,1,HIV infection
13096392,130963921,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00157,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130963921,DE,,,130963921,1,2012,,,,130963921,1,HIV infection
13096410,130964101,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00124,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964101,DE,,,130964101,1,2011,,,,130964101,1,HIV infection
13096411,130964111,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00118,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964111,DE,,,130964111,1,2011,,,,130964111,1,HIV infection
13096412,130964121,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00127,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964121,DE,,,130964121,1,2009,,,,130964121,1,HIV infection
13096413,130964131,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00116,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964131,DE,,,130964131,1,2010,,,,130964131,1,HIV infection
13096414,130964141,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00117,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964141,DE,,,130964141,1,2010,,,,130964141,1,HIV infection
13096415,130964151,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00113,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964151,DE,,,130964151,1,2011,,,,130964151,1,HIV infection
13096416,130964161,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00122,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964161,DE,,,130964161,1,2012,,,,130964161,1,HIV infection
13096417,130964171,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00114,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964171,DE,,,130964171,1,2009,,,,130964171,1,HIV infection
13096418,130964181,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00128,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964181,DE,,,130964181,1,2009,,,,130964181,1,HIV infection
13096419,130964191,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00105,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964191,DE,,,130964191,1,2009,,,,130964191,1,HIV infection
13096420,130964201,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00129,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964201,DE,,,130964201,1,2010,,,,130964201,1,HIV infection
13096421,130964211,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00126,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964211,DE,,,130964211,1,2013,,,,130964211,1,HIV infection
13096422,130964221,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00125,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964221,DE,,,130964221,1,2012,,,,130964221,1,HIV infection
13096423,130964231,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00130,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964231,DE,,,130964231,1,2012,,,,130964231,1,HIV infection
13096424,130964241,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00120,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964241,DE,,,130964241,1,2009,,,,130964241,1,HIV infection
13096425,130964251,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00123,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964251,DE,,,130964251,1,2013,,,,130964251,1,HIV infection
13096426,130964261,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00121,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964261,DE,,,130964261,1,2011,,,,130964261,1,HIV infection
13096429,130964291,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00115,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964291,DE,,,130964291,1,2009,,,,130964291,1,HIV infection
13096430,130964301,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00119,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964301,DE,,,130964301,1,2010,,,,130964301,1,HIV infection
13096436,130964361,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00158,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964361,DE,,,130964361,1,2012,,,,130964361,1,HIV infection
13096437,130964371,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00142,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Virologic failure,130964371,OT,,,130964371,1,2009,,,,130964371,1,HIV infection
13096438,130964381,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00139,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964381,DE,,,130964381,1,2012,,,,130964381,1,HIV infection
13096440,130964401,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00135,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964401,DE,,,130964401,1,2012,,,,130964401,1,HIV infection
13096442,130964421,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00131,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964421,DE,,,130964421,1,2012,,,,130964421,1,HIV infection
13096447,130964471,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00140,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Virologic failure,130964471,OT,,,130964471,1,2010,,,,130964471,1,HIV infection
13096448,130964481,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00161,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964481,DE,,,130964481,1,2010,,,,130964481,1,HIV infection
13096449,130964491,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00138,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964491,DE,,,130964491,1,2012,,,,130964491,1,HIV infection
13096451,130964511,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00137,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964511,DE,,,130964511,1,2010,,,,130964511,1,HIV infection
13096452,130964521,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00136,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964521,DE,,,130964521,1,2010,,,,130964521,1,HIV infection
13096453,130964531,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00159,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964531,DE,,,130964531,1,2011,,,,130964531,1,HIV infection
13096454,130964541,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00134,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964541,DE,,,130964541,1,2010,,,,130964541,1,HIV infection
13096456,130964561,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00162,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964561,DE,,,130964561,1,2010,,,,130964561,1,HIV infection
13096457,130964571,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00141,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Virologic failure,130964571,OT,,,130964571,1,2009,,,,130964571,1,HIV infection
13096458,130964581,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00132,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964581,DE,,,130964581,1,2009,,,,130964581,1,HIV infection
13096459,130964591,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00133,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964591,DE,,,130964591,1,2009,,,,130964591,1,HIV infection
13096461,130964611,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00143,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Virologic failure,130964611,OT,,,130964611,1,2009,,,,130964611,1,HIV infection
13096462,130964621,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00160,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Death,130964621,DE,,,130964621,1,2011,,,,130964621,1,HIV infection
13096463,130964631,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00144,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Virologic failure,130964631,OT,,,130964631,1,2013,,,,130964631,1,HIV infection
13096599,130965991,1,I,,20170103,20170109,20170109,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-000893,BRISTOL MYERS SQUIBB,,28,YR,,F,Y,,,20170109,,OT,NL,UG,EFAVIRENZ,Death,130965991,OT,,,,,,,,,130965991,1,Antiretroviral therapy
13096758,130967581,1,I,,20161226,20170109,20170109,EXP,,ET-CIPLA LTD.-2017ET00163,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170109,,OT,ET,ET,Efavirenz,Virologic failure,130967581,OT,,,130967581,1,2009,,,,130967581,1,HIV infection
13097222,130972221,1,I,,20170103,20170109,20170109,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-001082,BRISTOL MYERS SQUIBB,,,,,,Y,,,20170109,,OT,NL,UG,EFAVIRENZ,Bedridden;Death;Decreased appetite;Dehydration;Diarrhoea;Fatigue;Lethargy,130972221,OT,,,,,,,,,130972221,1,Antiretroviral therapy
13097918,130979181,1,I,,20170103,20170109,20170109,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-001083,BRISTOL MYERS SQUIBB,,38,YR,,F,Y,,,20170109,,OT,NL,UG,EFAVIRENZ,Anaemia;Asthenia;Disseminated tuberculosis;Leukopenia;Thrombocytopenia,130979181,DE,,,,,,,,,130979181,1,Antiretroviral therapy
13098560,130985601,1,I,,20170103,20170109,20170109,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-001084,BRISTOL MYERS SQUIBB,,22,YR,,F,Y,,,20170109,,OT,NL,UG,EFAVIRENZ,Diarrhoea;Drug-induced liver injury;Pancytopenia,130985601,OT,,,,,,,,,130985601,1,Antiretroviral therapy
13098568,130985681,1,I,,20170103,20170109,20170109,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-001086,BRISTOL MYERS SQUIBB,,32,YR,,F,Y,,,20170109,,OT,NL,UG,EFAVIRENZ,Cough;Diarrhoea;Leukopenia,130985681,OT,,,,,,,,,130985681,1,Antiretroviral therapy
13099056,130990561,1,I,20160822,20160913,20170109,20170109,EXP,,UG-GILEAD-2016-0233568,GILEAD,,54,YR,A,F,Y,79,KG,20170109,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hepatitis acute,130990561,OT,,,130990561,1,20160215,201609,,,130990561,1,HIV infection
13099374,130993741,1,I,,20170104,20170109,20170109,EXP,,US-GILEAD-2017-0252246,GILEAD,"GUPTA S-K, MCCOMSEY G-A, LOMBAARD J, ECHEVARRIA J, ORRELL C, AVIHINGSANON, OSIYEMI O, SANTOSCOY M, RAY N, STOCK D-A, JOSHI S-R, HANNA G-J, LATAILLADE M. EFFICACY, SAFETY, BONE AND METABOLIC EFFECTS OF HIV NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR BMS-986001 (AI467003): A PHASE 2B RANDOMISED, CONTROLLED, PARTLY BLINDED TRIAL. THE LANCET. 2016;3 (1):E13-22",,,A,,Y,,,20170109,,MD,US,US,EFAVIRENZ,Depression;Drug-induced liver injury,130993741,OT,,,,,,,,,130993741,1,HIV infection
13099776,130997761,1,I,,20161226,20170110,20170110,EXP,,ET-CIPLA LTD.-2017ET00001,CIPLA,"AWOKE T, WORKU A, KEBEDE Y, KASIM A, BIRLIE B, BRAEKERS R ET AL.,. MODELING OUTCOMES OF FIRST-LINE ANTIRETROVIRAL THERAPY AND RATE OF CD4 COUNTS CHANGE AMONG A COHORT OF HIV/AIDS PATIENTS IN ETHIOPIA: A RETROSPECTIVE COHORT STUDY. PLOS ONE. 2016;11 (12):1 TO 18",,,,,Y,,,20170110,,OT,ET,ET,Efavirenz,Death,130997761,DE,,,130997761,1,2010,,,,130997761,1,HIV infection
13100995,131009951,1,I,20140715,20170105,20170110,20170110,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2017GSK002037,VIIV,,28,YR,,F,Y,,,20170110,,CN,US,UG,EFAVIRENZ,Abortion spontaneous;Exposure during pregnancy,131009951,OT,,,131009951,1,20131010,20140619,,,131009951,1,HIV infection
13102542,131025421,1,I,,20170104,20170110,20170110,EXP,,US-GILEAD-2017-0252103,GILEAD,,51,YR,A,M,Y,,,20170110,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hip arthroplasty,131025421,OT,,,,,,,,,131025421,1,Product used for unknown indication
13102593,131025931,1,I,,20161228,20170110,20170110,EXP,,"AU-WARNER CHILCOTT, LLC-1061888",WARNER CHILCOTT,"JOURNAL: ENDOCRINE REVIEWS?AUTHOR: BURNS K, LAM T, CHIPPS DR?TITLE: ^HAART BREAK^ AN UNUSUAL CASE OF HIV RELATED BONE DISEASE?VOLUME: 36(2) YEAR: 2015",,,,M,Y,,,20170110,,OT,AU,AU,EFAVIRENZ,Atypical femur fracture,131025931,OT,,,,,,,,,,,
13102725,131027251,1,I,,20170103,20170110,20170110,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-001085,BRISTOL MYERS SQUIBB,,32,YR,,F,Y,,,20170110,,OT,NL,UG,EFAVIRENZ,Acute kidney injury;Diarrhoea;Drug-induced liver injury;Lung consolidation;Pancytopenia,131027251,DE,,,,,,,,,131027251,1,Antiretroviral therapy
13103037,131030371,1,I,,20170103,20170110,20170110,EXP,,MX-GILEAD-2017-0252129,GILEAD,"GUTIERREZ-DELGADO E-M, VILLANEUVA-LOZANO H, GARCIA ROJAS-ACOSTA M-J, MIRANDA-MALDONADO I-C, RAMOS-JIMENEZ J. A CASE REPORT OF SMALL BOWEL PERFORATION SECONDARY TO CYTOMEGALOVIRUS RELATED IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN AN AIDS PATIENT. ANNALS OF MEDICINE AND SURGERY. 2017;13:20-23",40,YR,A,M,Y,,,20170110,,OT,MX,MX,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Intestinal perforation;Large intestine perforation,131030371,OT,,,131030371,1,201506,,,,131030371,1,HIV infection
13105691,131056912,2,F,,20170116,20170111,20170116,EXP,,IL-VIIV HEALTHCARE LIMITED-IL2016GSK195660,VIIV,"MAHLAB-GURI K, ASHER I, ROSENBERG-BEZALEL S, ELBIRT D, BURKE M, STHOEGER ZM. TWO CASE REPORTS OF SEVERE MYOCARDITIS ASSOCIATED WITH THE INITIATION OF DOLUTEGRAVIR TREATMENT IN HIV PATIENTS. MEDICINE (UNITED STATES). 2016;95(47)",51,YR,,M,Y,,,20170116,,MD,IL,IL,Efavirenz,Cardiac failure;Dyspnoea;Dyspnoea exertional;Myocardial infarction;Myocarditis;Oedema peripheral;Sleep disorder;Ventricular dysfunction,131056912,HO,,,,,,,,,131056912,1,HIV infection
13106197,131061971,1,I,20131016,20170105,20170111,20170111,EXP,,UG-GILEAD-2017-0252414,GILEAD,,27,YR,A,F,Y,,,20170111,,MD,UG,UG,EFAVIRENZ,Abortion spontaneous;Death;Fall;Maternal exposure during pregnancy;Metrorrhagia,131061971,OT,,,131061971,1,20130723,20131121,,,131061971,1,HIV infection
13106609,131066091,1,I,20140715,20170105,20170111,20170111,EXP,,UG-GILEAD-2017-0252401,GILEAD,,28,YR,A,F,Y,,,20170111,,OT,UG,UG,EFAVIRENZ,Abortion spontaneous,131066091,OT,,,131066091,1,20140620,20140619,,,131066091,1,HIV infection
13109304,131093041,1,I,20161018,20170106,20170112,20170112,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-001793,BRISTOL MYERS SQUIBB,,47,YR,,M,Y,,,20170112,,CN,CN,CN,EFAVIRENZ,Bone marrow failure,131093041,OT,,,131093041,1,20160719,,,,131093041,1,Acquired immunodeficiency syndrome
13109865,131098651,1,I,20170105,20170110,20170112,20170112,EXP,,MZ-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-001807,BRISTOL MYERS SQUIBB,,43,YR,,F,Y,40,KG,20170112,,OT,MZ,MZ,EFAVIRENZ;EFAVIRENZ+LAMIVUDINE+TENOFOVIR DISOPROXIL FUM,Anaemia;Malaria,131098651,OT,,,131098651,1,20161026,20170106,,,131098651,1,HIV infection
13111151,131111511,1,I,20161206,20170106,20170112,20170112,EXP,,US-GILEAD-2017-0252748,GILEAD,,61,YR,A,F,Y,93.6,KG,20170112,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bronchitis,131111511,HO,,,131111511,1,20130222,,,,131111511,1,HIV infection
13111155,131111554,4,F,201612,20170127,20170112,20170203,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2016GSK157626,VIIV,,49,YR,,M,Y,,,20170203,,CN,CA,CA,Efavirenz,Aphonia;Dysphonia;Eczema;Hepatitis B;Intervertebral disc protrusion;Lumbar spinal stenosis;Nasopharyngitis;Nausea;Pulmonary pain;Sleep disorder;Syphilis,131111554,OT,,,131111554,2,20161025,,,,131111554,1,Product used for unknown indication
13111604,131116041,1,I,20160927,20170106,20170112,20170112,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-001799,BRISTOL MYERS SQUIBB,,68,YR,,M,Y,42,KG,20170112,,CN,CN,CN,EFAVIRENZ,Anaemia,131116041,HO,,,131116041,1,20160628,20160927,,,131116041,1,Acquired immunodeficiency syndrome
13113118,131131181,1,I,,20170102,20170113,20170113,EXP,,AU-VIIV HEALTHCARE LIMITED-AU2017GSK003722,VIIV,"BURNS K, LAM T, CHIPPS DR.. ^HAART BREAK^ AN UNUSUAL CASE OF HIV RELATED BONE DISEASE. ENDOCRINE REVIEW. 2015",51,YR,,M,Y,,,20170113,,OT,AU,AU,EFAVIRENZ,Blood phosphorus decreased;Fanconi syndrome;Femur fracture;Osteomalacia;Pathogen resistance,131131181,OT,,,,,,,,,131131181,2,Acquired immunodeficiency syndrome
13113259,131132591,1,I,,20170102,20170113,20170113,EXP,,AU-GLAXOSMITHKLINE-AU2017GSK003722,GLAXOSMITHKLINE,"BURNS K, LAM T, CHIPPS DR.. ^HAART BREAK^ AN UNUSUAL CASE OF HIV RELATED BONE DISEASE. ENDOCRINE REVIEW. 2015",51,YR,,M,Y,,,20170113,,OT,AU,AU,EFAVIRENZ,Blood phosphorus decreased;Fanconi syndrome;Femur fracture;Osteomalacia;Pathogen resistance,131132591,OT,,,,,,,,,131132591,2,Acquired immunodeficiency syndrome
13113685,131136851,1,I,20161007,20170106,20170113,20170113,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-001806,BRISTOL MYERS SQUIBB,,23,YR,,F,Y,56,KG,20170113,,CN,CN,CN,EFAVIRENZ,Hepatocellular injury,131136851,OT,,,131136851,1,20160816,20161007,,,131136851,1,Viral infection
13113690,131136901,1,I,,20170105,20170113,20170113,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-001020,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,,,20170113,,CN,UG,UG,EFAVIRENZ,Death;Maternal exposure during pregnancy,131136901,OT,,,131136901,1,20130723,20131121,,,131136901,1,HIV infection
13115651,131156511,1,I,,20170109,20170114,20170114,EXP,,CA-ABBVIE-17P-028-1839380-00,ABBVIE,,,,,M,Y,,,20170114,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,131156511,OT,,,,,,,,,131156511,1,Product used for unknown indication
13115921,131159211,1,I,20160125,20170105,20170115,20170115,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-001235,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20170115,,CN,UG,UG,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,131159211,OT,,,131159211,1,20150401,,,,131159211,1,HIV infection
13115922,131159221,1,I,20150607,20170105,20170115,20170115,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-001021,BRISTOL MYERS SQUIBB,,30,YR,,F,Y,,,20170115,,CN,ZW,ZW,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,131159221,OT,,,131159221,1,20140619,20150520,,,131159221,1,HIV infection
13116418,131164181,1,I,,20170106,20170116,20170116,EXP,,ZW-HETERO LABS LTD-1062034,HETERO,,30,YR,,F,Y,,,20170116,,OT,ZW,ZW,Efavirenz,Exposure during pregnancy;Stillbirth,131164181,DE,,,,,,,,,131164181,1,HIV infection
13118385,131183851,1,I,,20170104,20170116,20170116,EXP,,AU-APOTEX-2017AP005846,APOTEX,"BURNS K, LAM T, CHIPPS DR. HAART BREAK^ AN UNUSUAL CASE OF HIV RELATED BONE DISEASE.. ENDOCRINE REVIEWS. 2015;36",51,YR,,M,Y,,,20170116,,OT,AU,AU,EFAVIRENZ,Fanconi syndrome;Femur fracture;Hypophosphataemia;Osteomalacia,131183851,OT,,,,,,,,,131183851,1,Product used for unknown indication
13118772,131187721,1,I,,20170104,20170116,20170116,EXP,,AU-MYLANLABS-2017M1001472,MYLAN,"BURNS K, LAM T, CHIPPS DR. ^HAART BREAK^; AN UNUSUAL CASE OF HIV RELATED BONE DISEASE. ENDOCR-REV 2015.",,,,,Y,,,20170116,,OT,AU,AU,EFAVIRENZ,Femur fracture;Hypophosphataemia;Osteomalacia,131187721,OT,,,,,,,,,131187721,1,Hepatitis B
13120836,131208362,2,F,20140715,20170123,20170117,20170202,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-001237,BRISTOL MYERS SQUIBB,,28,YR,,F,Y,,,20170202,,OT,UG,UG,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,131208362,OT,,,131208362,1,20131010,20140619,,,131208362,1,HIV infection
13121296,131212961,1,I,,20170110,20170117,20170117,EXP,,PK-VIIV HEALTHCARE LIMITED-PK2017GSK005895,VIIV,KHAN EA. LESSONS FROM A SEVEN-YEAR EXPERIENCE OF PAEDIATRIC HIV IN PAKISTAN: A SINGLE CENTRE EXPERIENCE. J PAK MED ASSOC. 2017;67 (1):105 - 110,5,YR,,F,Y,,,20170117,,OT,PK,PK,Efavirenz,Drug resistance;Pathogen resistance;Treatment noncompliance,131212961,OT,,,,,,,,,131212961,1,HIV infection
13121453,131214531,1,I,,20170110,20170117,20170117,EXP,,PK-GLAXOSMITHKLINE-PK2017GSK005895,GLAXOSMITHKLINE,KHAN EA. LESSONS FROM A SEVEN-YEAR EXPERIENCE OF PAEDIATRIC HIV IN PAKISTAN: A SINGLE CENTRE EXPERIENCE. J PAK MED ASSOC. 2017;67 (1):105 - 110,5,YR,,F,Y,,,20170117,,OT,PK,PK,Efavirenz,Drug resistance;Pathogen resistance;Treatment noncompliance,131214531,OT,,,,,,,,,131214531,1,HIV infection
13122342,131223421,1,I,,20170106,20170117,20170117,EXP,,MX-MYLANLABS-2017M1001923,MYLAN,"GUTIERREZ-DELGADO EM, VILLANUEVA-LOZANO H, GARCIA ROJAS-ACOSTA MJ, MIRANDA-MALDONADO IC, RAMOS-JIMENEZ J. A CASE REPORT OF SMALL BOWEL PERFORATION SECONDARY TO CYTOMEGALOVIRUS RELATED IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN AN AIDS PATIENT. ANN-MED-SURGERY 2017;13:20-23.",,,,,Y,,,20170117,,OT,MX,MX,EFAVIRENZ,Immune reconstitution inflammatory syndrome;Jejunal perforation;Large intestine perforation,131223421,OT,,,,,,,,,131223421,1,Antiretroviral therapy
13123353,131233531,1,I,,20170112,20170117,20170117,EXP,,CA-GILEAD-2017-0253464,GILEAD,,69,YR,E,M,Y,,,20170117,,PH,CA,CA,EFAVIRENZ,Bone density decreased;Fracture;Osteopenia;Osteoporosis,131233531,HO,,,,,,,,,131233531,1,Antiretroviral therapy
13123395,131233951,1,I,201611,20170113,20170117,20170117,EXP,,GB-GILEAD-2017-0253595,GILEAD,,63,YR,A,M,Y,,,20170117,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,131233951,DE,,,,,,,,,131233951,1,Product used for unknown indication
13123491,131234914,4,F,20161130,20170222,20170117,20170228,EXP,,MW-GILEAD-2017-0253784,GILEAD,,30,YR,A,M,Y,69.7,KG,20170228,,OT,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Central nervous system infection,131234914,OT,,,131234914,1,20160407,20161124,,,131234914,1,Kaposi's sarcoma AIDS related
13126035,131260352,2,F,,20170112,20170118,20170120,EXP,,US-GILEAD-2016-0248393,GILEAD,,63,YR,A,M,Y,65.76,KG,20170120,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Creatinine renal clearance decreased,131260352,OT,,,,,,,,,131260352,1,HIV infection
13127462,131274622,2,F,20141115,20170116,20170118,20170123,EXP,,US-JNJFOC-20161213310,JANSSEN,,69,YR,E,M,Y,,,20170123,,CN,US,US,SUSTIVA,Haemorrhage intracranial;Seizure,131274622,HO,,,131274622,1,20140322,20141115,,,131274622,1,Thrombosis prophylaxis
13128182,131281822,2,F,,20170131,20170118,20170207,EXP,,CA-GILEAD-2017-0253472,GILEAD,,60,YR,A,M,Y,107,KG,20170207,,MD,CA,CA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,131281822,OT,,,131281822,3,20151225,20170122,,,131281822,1,Product used for unknown indication
13131426,131314261,1,I,,20161228,20170119,20170119,EXP,,AU-TEVA-727243ISR,TEVA,"BURNS K,LAM T,CHIPPS D. ^HAART BREAK^ AN UNUSUAL CASE OF HIV RELATED BONE DISEASE. ENDOCRINE REVIEWS. 2015 JAN 01;.",51,YR,,M,Y,,,20170119,,OT,AU,AU,efavirenz,Femur fracture;Hypophosphataemia;Osteomalacia,131314261,OT,,,,,,,,,131314261,2,HIV infection
13143518,131435181,1,I,,20170109,20170123,20170123,EXP,,AU-HETERO LABS LTD-1062320,HETERO,"JOURNAL: ENDOCR-REV 2015?AUTHOR: BURNS K, LAM T, CHIPPS DR.?TITLE: ^HAART BREAK^ AN UNUSUAL CASE OF HIV RELATED BONE DISEASE?YEAR: 2015",51,YR,,M,Y,,,20170123,,MD,AU,AU,Efavirenz,Fanconi syndrome;Osteomalacia,131435181,OT,,,,,,,,,131435181,1,HIV infection
13144218,131442188,8,F,20170116,20170316,20170124,20170330,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-004480,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20170330,,CN,BR,BR,EFAVIRENZ,Atrial septal defect;Cardiomegaly;Cerebral calcification;Cerebral cyst;Cerebral ventricle dilatation;Congenital central nervous system anomaly;Congenital cytomegalovirus infection;Dandy-Walker syndrome;Foetal cardiac disorder;Foetal exposure during pregnancy;Foetal growth restriction;HIV infection;Haemoglobin decreased;Microcephaly;Platelet count decreased;Platelet transfusion;Pneumonia cytomegaloviral;Premature baby;Skull malformation;Transfusion,131442188,OT,,,131442188,1,20161223,20170201,,,131442188,1,Prophylaxis against HIV infection
13145783,131457831,1,I,,20170123,20170124,20170124,EXP,,US-GILEAD-2017-0254859,GILEAD,,,,,M,Y,,,20170124,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood cholesterol increased;Diabetes mellitus;Product use issue,131457831,OT,,,,,,,,,131457831,1,Product used for unknown indication
13148975,131489757,7,F,20170116,20170309,20170125,20170316,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2017GSK007932,VIIV,,0,YR,,F,Y,62,KG,20170316,,MD,BR,BR,Efavirenz,Foetal malformation,131489757,HO,,,131489757,1,20161223,20161230,,,131489757,1,HIV infection
13148984,131489842,2,F,20170117,20170301,20170125,20170306,EXP,,CL-VIIV HEALTHCARE LIMITED-CL2017GSK007358,VIIV,,35,YR,,M,Y,,,20170306,,MD,CL,CL,EFAVIRENZ,Acute myocardial infarction;Coronary artery disease,131489842,HO,,,131489842,1,201104,,,,131489842,1,HIV infection
13150769,131507692,2,F,20170117,20170301,20170125,20170306,EXP,,CL-GLAXOSMITHKLINE-CL2017GSK007358,GLAXOSMITHKLINE,,35,YR,,M,Y,,,20170306,,MD,CL,CL,EFAVIRENZ,Acute myocardial infarction;Coronary artery disease,131507692,OT,,,131507692,1,201104,,,,131507692,1,HIV infection
13151111,131511112,2,F,20170103,20170118,20170125,20170127,EXP,,ZW-GILEAD-2017-0254565,GILEAD,,53,YR,A,M,Y,,,20170127,,OT,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Kaposi's sarcoma,131511112,OT,,,131511112,1,20151012,20170112,,,131511112,1,HIV infection
13159629,131596291,1,I,,20170119,20170127,20170127,EXP,,CN-MYLANLABS-2017M1004454,MYLAN,"XIAO H, XUE Y, GU S, WANG J, SUN H, LU H. EFFICACY AND SAFETY OF ANTIRETROVIRAL REGIMENS INCLUDING RALTEGRAVIR TO TREAT HIV-INFECTED PATIENTS WITH HEMOPHILIA. BIOSCI-TRENDS 2016;10(1):42-46.",,,,,Y,,,20170127,,OT,CN,CN,EFAVIRENZ,Osteoporosis,131596291,OT,,,,,,,,,131596291,1,HIV infection
13159639,131596391,1,I,,20170119,20170127,20170127,EXP,,CN-MYLANLABS-2017M1004418,MYLAN,"XIAO H, XUE Y, GU S, WANG J, SUN H, LU H. EFFICACY AND SAFETY OF ANTIRETROVIRAL REGIMENS INCLUDING RALTEGRAVIR TO TREAT HIV-INFECTED PATIENTS WITH HEMOPHILIA. BIOSCI-TRENDS 2016;10(1):42-46.",,,,,Y,,,20170127,,OT,CN,CN,EFAVIRENZ,Anaemia;Nightmare,131596391,OT,,,,,,,,,131596391,1,HIV infection
13159668,131596681,1,I,,20170123,20170127,20170127,EXP,,US-GILEAD-2017-0255004,GILEAD,"MAYER, K.H., ET AL.. EXCELLENT HIV POST-EXPOSURE PROPHYLAXIS REGIMEN COMPLETION WITH SINGLE TABLET DAILY ELVITEGRAVIR/COBICISTAT/TENOFOVIR DISIPROXIL FUMARATE/EMTRICITABINE COMPARED TO MORE FREQUENT DOSING REGIMENS. NOT AVAILABLE. NA;NA:NA",,,A,M,Y,,,20170127,,MD,US,US,EFAVIRENZ,Accidental overdose;Dizziness;Syncope;Vomiting,131596681,OT,,,,,,,,,131596681,1,Prophylaxis against HIV infection
13160396,131603964,4,F,20161222,20170310,20170127,20170314,EXP,,ZA-GILEAD-2017-0252974,GILEAD,,37,YR,A,F,Y,91.6,KG,20170314,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pyelonephritis acute,131603964,OT,,,131603964,1,20110831,,,,131603964,1,HIV infection
13165193,131651931,1,I,,20170116,20170130,20170130,EXP,,MX-HETERO LABS LTD-1062542,HETERO,,40,YR,,M,Y,,,20170130,,OT,MX,MX,Efavirenz\ Emtricitabine\Tenofovir,Immune reconstitution inflammatory syndrome;Intestinal perforation,131651931,OT,,,,,,,,,131651931,1,HIV infection
13169255,131692552,2,F,,20170126,20170131,20170202,EXP,,CA-GILEAD-2017-0255596,GILEAD,,56,YR,A,M,Y,,,20170202,,PH,CA,CA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diabetes mellitus;Osteoporosis,131692552,OT,,,131692552,1,,2014,,,131692552,1,Product used for unknown indication
13172512,131725121,1,I,,20161117,20170201,20170201,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2016US-128560,RANBAXY,,56,YR,,F,Y,62,KG,20170201,,OT,US,US,Efavirenz,Drug interaction;Renal tubular necrosis;Tubulointerstitial nephritis,131725121,OT,,,,,,,,,131725121,1,Hypertension
13174269,131742691,1,I,,20170127,20170131,20170131,EXP,,US-GILEAD-2017-0255876,GILEAD,,45,YR,A,M,Y,,,20170131,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Appendicitis;Immunodeficiency;Leukaemia;Malaise,131742691,OT,,,,,,,,,131742691,1,HIV infection
13175880,131758801,1,I,,20170127,20170201,20170201,EXP,,US-GILEAD-2017-0255896,GILEAD,,,,A,M,Y,,,20170201,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood cholesterol increased;Cardiac disorder;Stent placement;Vascular graft,131758801,OT,,,,,,,,,131758801,1,Product used for unknown indication
13175954,131759543,3,F,20170103,20170209,20170201,20170214,EXP,,MW-GILEAD-2017-0253792,GILEAD,,28,YR,A,F,Y,,,20170214,,OT,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug-induced liver injury,131759543,DE,,,131759543,1,20161116,20170102,,,131759543,1,Kaposi's sarcoma AIDS related
13176826,131768262,2,F,20170117,20170216,20170201,20170227,EXP,,UG-GILEAD-2017-0255961,GILEAD,,44,YR,A,M,Y,,,20170227,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bacteraemia,131768262,OT,,,131768262,1,20130703,20150504,,,131768262,1,Acquired immunodeficiency syndrome
13178908,131789081,1,I,20011001,20170125,20170202,20170202,PER,,US-PFIZER INC-2017044266,PFIZER,,36,YR,,M,Y,,,20170202,,PH,US,US,SUSTIVA,Abnormal dreams;Memory impairment;Somnambulism,,,,,131789081,3,20011001,,,,131789081,1,Depression
13179255,131792551,1,I,,20170127,20170202,20170202,EXP,,ZA-SCIEGEN PHARMACEUTICALS INC-2017SCILIT00024,SCIEGEN,,,,A,F,Y,,,20170202,,OT,ZA,ZA,Efavirenz,Stevens-Johnson syndrome,131792551,LT,,,,,,,,,131792551,1,Antiretroviral therapy
13179391,131793911,1,I,,20161228,20170202,20170202,EXP,,AU-SUN PHARMACEUTICAL INDUSTRIES LTD-2016RR-131044,RANBAXY,,51,YR,,M,Y,,,20170202,,OT,GB,AU,Efavirenz,Femur fracture;Hypophosphataemia;Osteomalacia;Pathogen resistance,131793911,OT,,,,,,,,,131793911,1,Product used for unknown indication
13188201,131882011,1,I,,20170131,20170206,20170206,EXP,,AR-VIIV HEALTHCARE LIMITED-AR2017GSK016403,VIIV,"CORDOVA E, MORGANTI L, RODRIGUEZ C.. POSSIBLE DRUG-HERB INTERACTION BETWEEN HERBAL SUPPLEMENT CONTAINING HORSETAIL (EQUISETUM ARVENSE) AND ANTIRETROVIRAL DRUGS: REPORT OF 2 CASES. JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE. 2017;16 (1):11-13",49,YR,,F,Y,,,20170206,,OT,AR,AR,EFAVIRENZ,Blood HIV RNA increased;Drug interaction,131882011,OT,,,,,,,,,131882011,1,HIV infection
13188203,131882031,1,I,,20170131,20170206,20170206,EXP,,AR-VIIV HEALTHCARE LIMITED-AR2017GSK016430,VIIV,"CORDOVA E, MORGANTI L, RODRIGUEZ C.. POSSIBLE DRUG-HERB INTERACTION BETWEEN HERBAL SUPPLEMENT CONTAINING HORSETAIL (EQUISETUM ARVENSE) AND ANTIRETROVIRAL DRUGS: REPORT OF 2 CASES. JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE. 2017;16 (1):11-13",75,YR,,M,Y,,,20170206,,OT,AR,AR,EFAVIRENZ,Blood HIV RNA increased;Drug interaction,131882031,OT,,,,,,,,,131882031,1,HIV infection
13188679,131886791,1,I,,20170131,20170206,20170206,EXP,,AR-GLAXOSMITHKLINE-AR2017GSK016403,GLAXOSMITHKLINE,"CORDOVA E, MORGANTI L, RODRIGUEZ C.. POSSIBLE DRUG-HERB INTERACTION BETWEEN HERBAL SUPPLEMENT CONTAINING HORSETAIL (EQUISETUM ARVENSE) AND ANTIRETROVIRAL DRUGS: REPORT OF 2 CASES. JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE. 2017;16 (1):11-13",49,YR,,F,Y,,,20170206,,OT,AR,AR,EFAVIRENZ,Blood HIV RNA increased;Drug interaction,131886791,OT,,,,,,,,,131886791,1,HIV infection
13188688,131886881,1,I,,20170131,20170206,20170206,EXP,,AR-GLAXOSMITHKLINE-AR2017GSK016430,GLAXOSMITHKLINE,"CORDOVA E, MORGANTI L, RODRIGUEZ C.. POSSIBLE DRUG-HERB INTERACTION BETWEEN HERBAL SUPPLEMENT CONTAINING HORSETAIL (EQUISETUM ARVENSE) AND ANTIRETROVIRAL DRUGS: REPORT OF 2 CASES. JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE. 2017;16 (1):11-13",75,YR,,M,Y,,,20170206,,OT,AR,AR,EFAVIRENZ,Blood HIV RNA increased;Drug interaction,131886881,OT,,,,,,,,,131886881,1,HIV infection
13194934,131949341,1,I,20170127,20170201,20170207,20170207,EXP,,US-GILEAD-2017-0256649,GILEAD,,47,YR,A,M,Y,,,20170207,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Liver transplant;Unevaluable event,131949341,HO,,,,,,,,,131949341,1,Product used for unknown indication
13195465,131954654,4,F,20170201,20170323,20170208,20170329,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-010413,BRISTOL MYERS SQUIBB,,15,YR,,F,Y,62,KG,20170329,,CN,BR,BR,EFAVIRENZ,Caesarean section;Folliculitis;Maternal exposure during pregnancy;Premature delivery,131954654,OT,,,131954654,1,20161223,20170201,,,131954654,1,HIV infection
13195796,131957961,1,I,,20170125,20170208,20170208,EXP,,CN-HETERO LABS LTD-1062868,HETERO,"XIAO H, XUE Y, GU S, WANG J, SUN H, LU H. EFFICACY AND SAFETY OF ANTIRETROVIRAL REGIMENS INCLUDING RALTEGRAVIR TO TREAT HIV-INFECTED PATIENTS WITH HEMOPHILIA. BIOSCI-TRENDS 2016;10 (1):42-46",38,YR,,,Y,,,20170208,,OT,CN,CN,Efavirenz\ lamivudine \ Tenofovir  disoproxil fumarate,Osteoporosis,131957961,OT,,,,,,,,,131957961,1,HIV infection
13196502,131965028,8,F,20170201,20170309,20170208,20170317,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2017GSK015761,VIIV,,0,DY,,F,Y,1.89,KG,20170317,,MD,BR,BR,Efavirenz,Atrial septal defect;Congenital cytomegalovirus infection,131965028,CA,,,131965028,1,20161223,20170201,,,131965028,1,HIV infection
13199367,131993671,1,I,,20170202,20170208,20170208,EXP,,US-GILEAD-2017-0256926,GILEAD,,40,YR,A,M,Y,,,20170208,,PH,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Central nervous system lesion,131993671,OT,,,,,,,,,131993671,1,HIV infection
13200879,132008791,1,I,,20170131,20170209,20170209,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-008961,BRISTOL MYERS SQUIBB,,56,YR,,M,Y,,,20170209,,CN,US,CA,EFAVIRENZ,Osteoporosis,132008791,OT,,,,,,,,,132008791,1,Product used for unknown indication
13203543,132035431,1,I,,20170201,20170209,20170209,EXP,,RO-VIIV HEALTHCARE LIMITED-RO2017GSK015282,VIIV,"GAVRILIU LC, BENEA OE,. HIV ASSOCIATED LYMPHOMA -TWO CASE REPORT SERIES. ROMANIAN JOURNAL OF INFECTIOUS DISEASES. 2016;XIX(3):157-165",27,YR,,M,Y,,,20170209,,MD,RO,RO,EFAVIRENZ,Asthenia;CD4 lymphocytes abnormal;Cough;Hepatic enzyme increased;Hepatomegaly;Hodgkin's disease;Hyperhidrosis;Leukopenia;Lymphadenopathy;Lymphopenia;Microcytic anaemia;Splenomegaly;Thrombocytopenia,132035431,HO,,,,,,,,,132035431,2,Antiretroviral therapy
13203766,132037665,5,F,20170110,20170320,20170208,20170328,EXP,,TH-GILEAD-2017-0256663,GILEAD,,28,YR,A,M,Y,69.9,KG,20170328,,OT,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Substance-induced psychotic disorder,132037665,HO,,,132037665,1,20160125,20170109,,,132037665,1,HIV infection
13204147,132041471,1,I,,20170201,20170209,20170209,EXP,,RO-GLAXOSMITHKLINE-RO2017GSK015282,GLAXOSMITHKLINE,"GAVRILIU LC, BENEA OE,. HIV ASSOCIATED LYMPHOMA -TWO CASE REPORT SERIES. ROMANIAN JOURNAL OF INFECTIOUS DISEASES. 2016;XIX(3):157-165",27,YR,,M,Y,,,20170209,,MD,RO,RO,EFAVIRENZ,Asthenia;CD4 lymphocytes abnormal;Cough;Hepatic enzyme increased;Hepatomegaly;Hodgkin's disease;Hyperhidrosis;Leukopenia;Lymphadenopathy;Lymphopenia;Microcytic anaemia;Splenomegaly;Thrombocytopenia,132041471,OT,,,,,,,,,132041471,2,Antiretroviral therapy
13204411,132044114,4,F,20170112,20170315,20170208,20170328,EXP,,GB-GILEAD-2017-0256895,GILEAD,,53,YR,A,M,Y,111.8,KG,20170328,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abscess limb,132044114,HO,,,132044114,1,20110225,,,,132044114,1,HIV infection
13214799,132147991,1,I,,20170207,20170210,20170210,EXP,,CN-PFIZER INC-2017056653,PFIZER,"ZUO, S.. CLINICAL ANALYSIS OF FIVE CASES OF AIDS-RELATED NON-HODGKIN LYMPHOMA. PAKISTAN JOURNAL OF MEDICAL SCIENCES. 2016;32 (6):1574-1579",28,YR,,M,Y,,,20170210,,MD,CN,CN,EFAVIRENZ,Bone marrow failure;Sepsis,132147991,OT,,,,,,,,,132147991,1,Non-Hodgkin's lymphoma
13215050,132150501,1,I,20160629,20160706,20170210,20170210,EXP,,MW-GILEAD-2016-0223379,GILEAD,,34,YR,A,M,Y,59.5,KG,20170210,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bacterial sepsis,132150501,OT,,,132150501,1,20160628,20160629,,,132150501,1,Kaposi's sarcoma AIDS related
13216665,132166651,1,I,19980223,20030226,20170210,20170210,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-12197463,BRISTOL MYERS SQUIBB,,23,YR,,M,Y,54,KG,20170210,,OT,JP,JP,EFAVIRENZ,Cachexia;Hyperlactacidaemia;Osteonecrosis;Platelet count decreased,132166651,DS,,,132166651,1,19980114,20040527,,,132166651,1,HIV infection
13220170,132201701,1,I,,20170204,20170210,20170210,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-010253,BRISTOL MYERS SQUIBB,,,,,F,Y,1.89,KG,20170210,,CN,BR,BR,EFAVIRENZ,Atrial septal defect;Foetal exposure during pregnancy;Premature baby,132201701,HO,,,132201701,1,20161223,20170201,,,132201701,1,Product used for unknown indication
13220172,132201721,1,I,20170201,20170204,20170210,20170210,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-011279,BRISTOL MYERS SQUIBB,,15,YR,,F,Y,,,20170210,,CN,BR,BR,EFAVIRENZ,Maternal exposure during pregnancy;Premature delivery,132201721,OT,,,132201721,1,20161223,20170201,,,132201721,1,HIV infection
13229601,132296011,1,I,,20170201,20170214,20170214,EXP,,UG-CIPLA LTD.-2017UG01842,CIPLA,,,,,,Y,,,20170214,,OT,SG,UG,Efavirenz,Virologic failure,132296011,OT,,,,,,,,,132296011,1,HIV infection
13229628,132296281,1,I,,20170201,20170214,20170214,EXP,,UG-CIPLA LTD.-2017UG01843,CIPLA,,,,,,Y,,,20170214,,OT,SG,UG,Efavirenz,Virologic failure,132296281,OT,,,,,,,,,132296281,1,HIV infection
13229635,132296351,1,I,,20170201,20170214,20170214,EXP,,UG-CIPLA LTD.-2017UG01847,CIPLA,,,,,,Y,,,20170214,,OT,SG,UG,Efavirenz,Virologic failure,132296351,OT,,,,,,,,,132296351,1,HIV infection
13229645,132296451,1,I,,20170201,20170214,20170214,EXP,,UG-CIPLA LTD.-2017UG01845,CIPLA,,,,,,Y,,,20170214,,OT,SG,UG,Efavirenz,Virologic failure,132296451,OT,,,,,,,,,132296451,1,HIV infection
13229655,132296551,1,I,,20170201,20170214,20170214,EXP,,UG-CIPLA LTD.-2017UG01844,CIPLA,,,,,,Y,,,20170214,,OT,SG,UG,Efavirenz,Virologic failure,132296551,OT,,,,,,,,,132296551,1,HIV infection
13229666,132296661,1,I,,20170201,20170214,20170214,EXP,,UG-CIPLA LTD.-2017UG01850,CIPLA,,,,,,Y,,,20170214,,OT,SG,UG,Efavirenz,Virologic failure,132296661,OT,,,,,,,,,132296661,1,HIV infection
13229673,132296731,1,I,,20170201,20170214,20170214,EXP,,UG-CIPLA LTD.-2017UG01848,CIPLA,,,,,,Y,,,20170214,,OT,SG,UG,Efavirenz,Virologic failure,132296731,OT,,,,,,,,,132296731,1,HIV infection
13229681,132296811,1,I,,20170201,20170214,20170214,EXP,,UG-CIPLA LTD.-2017UG01851,CIPLA,,,,,,Y,,,20170214,,OT,SG,UG,Efavirenz,Virologic failure,132296811,OT,,,,,,,,,132296811,1,HIV infection
13231318,132313181,1,I,20161128,20170206,20170214,20170214,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-012241,BRISTOL MYERS SQUIBB,,55,YR,,M,Y,65,KG,20170214,,CN,CN,CN,EFAVIRENZ,Renal impairment,132313181,DS,,,132313181,1,20160920,20161128,,,132313181,1,Viral infection
13231333,132313332,2,F,20170206,20170320,20170214,20170324,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-011471,BRISTOL MYERS SQUIBB,,,,,M,Y,2.8,KG,20170324,,OT,BR,BR,EFAVIRENZ,Ankyloglossia congenital;Bradycardia neonatal;Foetal distress syndrome;Foetal exposure during pregnancy;Meconium abnormal;Neonatal respiratory depression,132313332,CA,,,132313332,1,20161021,20170205,,,132313332,1,Product used for unknown indication
13232769,132327691,1,I,20170203,20170207,20170214,20170214,EXP,,MW-GILEAD-2017-0257956,GILEAD,,29,YR,A,M,Y,,,20170214,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Sepsis,132327691,OT,,,132327691,1,20170202,20170202,,,132327691,1,Kaposi's sarcoma AIDS related
13233537,132335371,1,I,,20170201,20170215,20170215,EXP,,UG-CIPLA LTD.-2017UG01857,CIPLA,,,,,,Y,,,20170215,,OT,SG,UG,Efavirenz,Virologic failure,132335371,OT,,,,,,,,,132335371,1,HIV infection
13233548,132335481,1,I,,20170201,20170215,20170215,EXP,,UG-CIPLA LTD.-2017UG01860,CIPLA,,,,,,Y,,,20170215,,OT,SG,UG,Efavirenz,Virologic failure,132335481,OT,,,,,,,,,132335481,1,HIV infection
13233550,132335501,1,I,,20170201,20170215,20170215,EXP,,UG-CIPLA LTD.-2017UG01854,CIPLA,,,,,,Y,,,20170215,,OT,SG,UG,Efavirenz,Virologic failure,132335501,OT,,,,,,,,,132335501,1,HIV infection
13233556,132335561,1,I,,20170206,20170215,20170215,EXP,,CN-ROCHE-1893624,ROCHE,"ZUO S, XU N, LI Z, LI N, XIA H, REN H AND BAO H. CLINICAL ANALYSIS OF FIVE CASES OF AIDS-RELATED NON-HODGKIN LYMPHOMA. PAKISTAN JOURNAL OF MEDICAL SCIENCES 2016 NOV;32 (6):1574-1579.",27,YR,,M,Y,,,20170215,,MD,CN,CN,EFAVIRENZ,Bone marrow failure;Gastrointestinal disorder,132335561,OT,,,,,,,,,132335561,1,Non-Hodgkin's lymphoma
13233557,132335571,1,I,,20170201,20170215,20170215,EXP,,UG-CIPLA LTD.-2017UG01862,CIPLA,,,,,,Y,,,20170215,,OT,SG,UG,Efavirenz,Virologic failure,132335571,OT,,,,,,,,,132335571,1,HIV infection
13233562,132335621,1,I,,20170201,20170215,20170215,EXP,,UG-CIPLA LTD.-2017UG01864,CIPLA,,,,,,Y,,,20170215,,OT,SG,UG,Efavirenz,Virologic failure,132335621,OT,,,,,,,,,132335621,1,HIV infection
13233581,132335811,1,I,,20170201,20170215,20170215,EXP,,UG-CIPLA LTD.-2017UG01865,CIPLA,,,,,,Y,,,20170215,,OT,SG,UG,Efavirenz,Virologic failure,132335811,OT,,,,,,,,,132335811,1,HIV infection
13233659,132336591,1,I,,20170201,20170215,20170215,EXP,,UG-CIPLA LTD.-2017UG01868,CIPLA,,,,,,Y,,,20170215,,OT,SG,UG,Efavirenz,Virologic failure,132336591,OT,,,,,,,,,132336591,1,HIV infection
13233665,132336651,1,I,,20170201,20170215,20170215,EXP,,UG-CIPLA LTD.-2017UG01870,CIPLA,,,,,,Y,,,20170215,,OT,SG,UG,Efavirenz,Virologic failure,132336651,OT,,,,,,,,,132336651,1,HIV infection
13237115,132371151,1,I,,20170204,20170215,20170215,EXP,,FR-MYLANLABS-2017M1008628,MYLAN,"BARTHELEMY A, BOUVIER N, VERDON R, CHATELET V, HURAULT DE LIGNY B. SUCCESSFUL RENAL RETRANSPLANTATION AFTER GRAFT LOSS FROM BK POLYOMAVIRUS INFECTION IN A HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE PATIENT. TRANSPL-INFECT-DIS 2016;18(6):946-949.",,,,,Y,,,20170215,,OT,FR,FR,EFAVIRENZ,BK virus infection;Neutropenia;Polyomavirus-associated nephropathy;Transplant failure,132371151,OT,,,,,,,,,132371151,1,Immunosuppressant drug therapy
13237815,132378151,1,I,20170103,,20170215,20170215,DIR,FDA-CDER-CTU-2017-9028,,FDA-CTU,,28,YR,,F,N,56.8,KG,20170119,Y,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF,Abdominal pain;Anaemia;Bacterial sepsis;Blood glucose increased;Chest pain;Crepitations;Drug dose omission;Drug-induced liver injury;Encephalopathy;Hepatorenal failure;Hepatosplenomegaly;Hyporeflexia;Hypotension;Hypotonia;Loss of consciousness;Malaria;Mucosal dryness;Multiple organ dysfunction syndrome;Neutrophil count increased;Oedema peripheral;Oral candidiasis;Pulse absent;Pupil fixed;Renal failure;Respiratory distress;Tachycardia,132378151,DE,132378151,HP,132378151,1,20161116,20161212,,,132378151,1,Kaposi's sarcoma
13240566,132405661,1,I,201607,20161115,20170216,20170216,PER,,US-RELYPSA-RLY2016003871,RELYPSA,,60,YR,,M,Y,,,20170214,,CN,US,US,SUSTIVA,Drug dose omission;Pruritus;Rash pruritic;Skin haemorrhage,,,,,132405661,1,20160727,,,,132405661,1,Hyperkalaemia
13240880,132408802,2,F,,20170227,20170216,20170303,EXP,,ES-GILEAD-2017-0258280,GILEAD,,,,A,,Y,,,20170303,,MD,ES,ES,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bacterial sepsis;Diarrhoea;Drug interaction;Neurotoxicity;Renal colic;Treatment noncompliance;Virologic failure,132408802,OT,,,,,,,,,132408802,1,HIV infection
13245399,132453991,1,I,,20170206,20170217,20170217,EXP,,FR-CIPLA LTD.-2017FR01968,CIPLA,"GALLIEN S, JOURNOT V, LORIOT MA, SAUVAGEON H, MORLAT P, REYNES J ET AL.,. CYTOCHROME 2B6 POLYMORPHISM AND EFAVIRENZ-INDUCED CENTRAL NERVOUS SYSTEM SYMPTOMS : A SUBSTUDY OF THE ANRS ALIZE TRIAL. HIV MEDICINE. 2017;1 TO 9",,,,,Y,,,20170217,,OT,FR,FR,Efavirenz,Nervous system disorder,132453991,OT,,,,,,,,,132453991,1,HIV infection
13245401,132454011,1,I,,20170206,20170217,20170217,EXP,,FR-CIPLA LTD.-2017FR01981,CIPLA,"GALLIEN S, JOURNOT V, LORIOT MA, SAUVAGEON H, MORLAT P, REYNES J, ET.AL,. CYTOCHROME 2B6 POLYMORPHISM AND EFAVIRENZ-INDUCED CENTRAL NERVOUS SYSTEM SYMPTOMS : A SUBSTUDY OF THE ANRS ALIZE TRIAL. HIV MEDICINE. 2017;1 TO 9",,,,,Y,,,20170217,,OT,FR,FR,Efavirenz,Nervous system disorder,132454011,OT,,,,,,,,,132454011,1,HIV infection
13245403,132454031,1,I,,20170206,20170217,20170217,EXP,,FR-CIPLA LTD.-2017FR01982,CIPLA,"GALLIEN S, JOURNOT V, LORIOT MA, SAUVAGEON H, MORLAT P, REYNES J, ET.AL;. CYTOCHROME 2B6 POLYMORPHISM AND EFAVIRENZ-INDUCED CENTRAL NERVOUS SYSTEM SYMPTOMS : A SUBSTUDY OF THE ANRS ALIZE TRIAL. HIV MEDICINE. 2017;1 TO 9",,,,,Y,,,20170217,,OT,FR,FR,Efavirenz,Nervous system disorder,132454031,OT,,,,,,,,,132454031,1,HIV infection
13245405,132454051,1,I,,20170206,20170217,20170217,EXP,,FR-CIPLA LTD.-2017FR01967,CIPLA,"GALLIEN S, JOURNOT V, LORIOT MA, SAUVAGEON H, MORLAT P, REYNES J ET AL.,. CYTOCHROME 2B6 POLYMORPHISM AND EFAVIRENZ-INDUCED CENTRAL NERVOUS SYSTEM SYMPTOMS: A SUBSTUDY OF THE ANRS ALIZE TRIAL. HIV MEDICINE. 2017;1 TO 9",,,,,Y,,,20170217,,OT,FR,FR,Efavirenz,Depression;Suicidal ideation;Suicide attempt,132454051,OT,,,,,,,,,132454051,1,HIV infection
13245407,132454071,1,I,,20170206,20170217,20170217,EXP,,FR-CIPLA LTD.-2017FR01969,CIPLA,"GALLIEN S, JOURNOT V, LORIOT MA, SAUVAGEON H, MORLAT P, REYNES J ET AL.,. CYTOCHROME 2B6 POLYMORPHISM AND EFAVIRENZ-INDUCED CENTRAL NERVOUS SYSTEM SYMPTOMS : A SUBSTUDY OF THE ANRS ALIZE TRIAL. HIV MEDICINE. 2017;1 TO 9",,,,,Y,,,20170217,,OT,FR,FR,Efavirenz,Nervous system disorder,132454071,OT,,,,,,,,,132454071,1,HIV infection
13245409,132454091,1,I,,20170206,20170217,20170217,EXP,,FR-CIPLA LTD.-2017FR01980,CIPLA,"GALLIEN S, JOURNOT V, LORIOT MA, SAUVAGEON H, MORLAT P, REYNES J ET AL.,. CYTOCHROME 2B6 POLYMORPHISM AND EFAVIRENZ-INDUCED CENTRAL NERVOUS SYSTEM SYMPTOMS : A SUBSTUDY OF THE ANRS ALIZE TRIAL. HIV MEDICINE. 2017;1 TO 9",,,,,Y,,,20170217,,OT,FR,FR,Efavirenz,Nervous system disorder,132454091,OT,,,,,,,,,132454091,1,HIV infection
13245414,132454141,1,I,,20170206,20170217,20170217,EXP,,FR-CIPLA LTD.-2017FR01971,CIPLA,"GALLIEN S, JOURNOT V, LORIOT MA, SAUVAGEON H, MORLAT P, REYNES J ET AL.,. CYTOCHROME 2B6 POLYMORPHISM AND EFAVIRENZ-INDUCED CENTRAL NERVOUS SYSTEM SYMPTOMS : A SUBSTUDY OF THE ANRS ALIZE TRIA. HIV MEDICINE. 2017;1 TO 9",,,,,Y,,,20170217,,OT,FR,FR,Efavirenz,Nervous system disorder,132454141,OT,,,,,,,,,132454141,1,HIV infection
13246572,132465721,1,I,20161202,20170207,20170217,20170217,EXP,,PL-GILEAD-2017-0257664,GILEAD,,35,YR,A,M,Y,81.1,KG,20170217,,OT,PL,PL,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Epididymitis;Orchitis noninfective,132465721,HO,,,132465721,1,20110204,,,,132465721,1,HIV infection
13246639,132466391,1,I,,20170206,20170217,20170217,EXP,,FR-CIPLA LTD.-2017FR01983,CIPLA,"GALLIEN S, JOURNOT V, LORIOT MA, SAUVAGEON H, MORLAT P, REYNES J, ET.AL;. CYTOCHROME 2B6 POLYMORPHISM AND EFAVIRENZ-INDUCED CENTRAL NERVOUS SYSTEM SYMPTOMS : A SUBSTUDY OF THE ANRS ALIZE TRIAL. HIV MEDICINE. 2017;1 TO 9",,,,,Y,,,20170217,,OT,FR,FR,Efavirenz,Nervous system disorder,132466391,OT,,,,,,,,,132466391,1,HIV infection
13246688,132466881,1,I,,20170206,20170217,20170217,EXP,,FR-CIPLA LTD.-2017FR01970,CIPLA,"GALLIEN S, JOURNOT V, LORIOT MA, SAUVAGEON H, MORLAT P, REYNES J ET AL.,. CYTOCHROME 2B6 POLYMORPHISM AND EFAVIRENZ-INDUCED CENTRAL NERVOUS SYSTEM SYMPTOMS : A SUBSTUDY OF THE ANRS ALIZE TRIAL. HIV MEDICINE. 2017;1 TO 9",,,,,Y,,,20170217,,OT,FR,FR,Efavirenz,Nervous system disorder,132466881,OT,,,,,,,,,132466881,1,HIV infection
13251089,132510891,1,I,,20170131,20170220,20170220,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-008805,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20170220,,CN,US,US,SUSTIVA,Adverse event,,,,,,,,,,,132510891,1,Product used for unknown indication
13252033,132520333,3,F,,20170227,20170220,20170307,EXP,,ES-VIIV HEALTHCARE LIMITED-ES2017022671,VIIV,UNK. LAMIVUDINE PLUS DARNAVIR POTENTIATED AS DUAL THERAPY IN HIV PATIENTS WITH NUCLEOSIDE ANALOGUE TOXICITY OR IN THE PRESENCE OF COMMORBIDITIES (LAMDA STUDY). MEDED INFECTIOUS DISEASES 2017. 2017;UNK:UNK,,,A,,Y,,,20170307,,MD,ES,ES,EFAVIRENZ,Bacterial sepsis;Diarrhoea;Drug interaction;Neurotoxicity;Renal colic;Treatment noncompliance;Virologic failure,132520333,DE,,,,,,,,,132520333,1,HIV infection
13252162,132521623,3,F,,20170227,20170220,20170307,EXP,,ES-GLAXOSMITHKLINE-ES2017022671,GLAXOSMITHKLINE,UNK. LAMIVUDINE PLUS DARNAVIR POTENTIATED AS DUAL THERAPY IN HIV PATIENTS WITH NUCLEOSIDE ANALOGUE TOXICITY OR IN THE PRESENCE OF COMMORBIDITIES (LAMDA STUDY). MEDED INFECTIOUS DISEASES 2017. 2017;UNK:UNK,,,A,,Y,,,20170307,,MD,ES,ES,EFAVIRENZ,Bacterial sepsis;Diarrhoea;Drug interaction;Neurotoxicity;Renal colic;Treatment noncompliance;Virologic failure,132521623,DE,,,,,,,,,132521623,1,HIV infection
13254316,132543161,1,I,,20170214,20170221,20170221,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-012875,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20170221,,CN,US,US,SUSTIVA,Laryngitis;Upper respiratory tract infection,,,,,,,,,,,132543161,1,Product used for unknown indication
13255423,132554231,1,I,,20170213,20170221,20170221,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-012395,BRISTOL MYERS SQUIBB,,,,,,Y,,,20170221,,MD,GB,GB,SUSTIVA,Gastrostomy;Product use issue,132554231,OT,,,,,,,,,132554231,1,Product used for unknown indication
13257832,132578321,1,I,,20170207,20170221,20170221,EXP,,GB-GLAXOSMITHKLINE-GB2017GSK018157,GLAXOSMITHKLINE,,50,YR,,,Y,,,20170221,,CN,GB,GB,SUSTIVA,Anxiety;Memory impairment;Nightmare;Paraesthesia;Renal impairment,132578321,OT,,,,,,,,,132578321,1,HIV infection
13257842,132578421,1,I,,20170207,20170221,20170221,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2017GSK018157,VIIV,,50,YR,,,Y,,,20170221,,CN,GB,GB,SUSTIVA,Anxiety;Memory impairment;Nightmare;Paraesthesia;Renal impairment,132578421,OT,,,,,,,,,132578421,1,HIV infection
13258114,132581141,1,I,20160704,20170209,20170221,20170221,EXP,,MW-GILEAD-2017-0258042,GILEAD,,35,YR,A,M,Y,,,20170221,,OT,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Blood albumin decreased;Kaposi's sarcoma;Weight decreased,132581141,OT,,,132581141,1,20150715,20170204,,,132581141,1,Acquired immunodeficiency syndrome
13268621,132686212,2,F,,20170220,20170224,20170302,EXP,,FR-TEVA-741890ISR,TEVA,"BARTHELEMY A,BOUVIER N,VERDON R,HURAULT DE LIGNY B. MULTIPLE DRUGS BK VIRUS INFECTION INDUCED NEPHROPATHY CAUSING GRAFT FAILURE. REACTIONS WEEKLY. 2017 JAN 01;1638:160.",51,YR,,M,Y,,,20170302,,OT,FR,FR,efavirenz,BK virus infection;Nephropathy;Neutropenia;Transplant failure,132686212,OT,,,,,,,,,132686212,1,Immunosuppressant drug therapy
13274205,132742051,1,I,,20170215,20170227,20170227,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-016053,BRISTOL MYERS SQUIBB,,28,YR,,F,Y,,,20170227,,OT,FR,FR,EFAVIRENZ,Abortion induced;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue,132742051,OT,,,132742051,1,201110,,,,132742051,1,HIV infection
13274215,132742151,1,I,,20170215,20170227,20170227,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-015407,BRISTOL MYERS SQUIBB,,32,YR,,F,Y,,,20170227,,OT,FR,FR,EFAVIRENZ,Abortion induced;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue,132742151,OT,,,132742151,1,200909,,,,132742151,1,HIV infection
13274309,132743092,2,F,,20170310,20170227,20170315,EXP,,TR-GILEAD-2017-0259775,GILEAD,,44,YR,A,M,Y,82,KG,20170315,,MD,TR,TR,EFAVIRENZ,Coronary artery disease,132743092,OT,,,,,,,,,132743092,1,HIV infection
13274317,132743172,2,F,,20170310,20170227,20170315,EXP,,TR-GILEAD-2017-0259777,GILEAD,,31,YR,A,M,Y,,,20170315,,MD,TR,TR,EFAVIRENZ,Non-Hodgkin's lymphoma,132743172,OT,,,,,,,,,132743172,1,HIV infection
13274653,132746531,1,I,,20170220,20170227,20170227,EXP,,US-TEVA-743148USA,TEVA,"HAUG SJ, WONG RW, DAY S, CHOUDHRY N, SNEED S, PRASAD P, ET AL. DIDANOSINE RETINAL TOXICITY. RETINA 2016;36 (SUPPL. 1):S159-S167.",66,YR,,M,Y,,,20170227,,MD,US,US,efavirenz,Retinal toxicity,132746531,OT,,,,,,,,,132746531,1,Antiretroviral therapy
13275773,132757731,1,I,201603,20170206,20170228,20170228,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-010596,BRISTOL MYERS SQUIBB,,10,YR,,F,Y,,,20170228,,PH,US,US,SUSTIVA,Off label use,,,,,132757731,1,201603,,,,132757731,1,HIV infection
13278413,132784133,3,F,20170201,20170323,20170228,20170329,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-015623,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20170329,,OT,BR,BR,EFAVIRENZ,Caesarean section;Maternal exposure during pregnancy;Premature delivery,132784133,OT,,,132784133,1,20161223,20170201,,,132784133,1,HIV infection
13278414,132784145,5,F,20170116,20170321,20170228,20170324,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-009368,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20170324,,OT,BR,BR,EFAVIRENZ,Atrial septal defect;Cardiomegaly;Cerebral calcification;Cerebral cyst;Cerebral ventricle dilatation;Congenital central nervous system anomaly;Congenital cytomegalovirus infection;Dandy-Walker syndrome;Foetal cardiac disorder;Foetal exposure during pregnancy;Foetal growth restriction;HIV infection;Haemoglobin decreased;Microcephaly;Platelet count decreased;Platelet transfusion;Pneumonia cytomegaloviral;Premature baby;Skull malformation;Transfusion,132784145,HO,,,132784145,1,20161223,20170201,,,132784145,1,Prophylaxis against HIV infection
13278460,132784601,1,I,,20170215,20170228,20170228,EXP,,FR-009507513-1702FRA008506,MERCK,,32,YR,,F,Y,,,20170228,,CN,US,FR,EFAVIRENZ,Abortion induced;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue,132784601,OT,,,132784601,1,200909,,,,132784601,1,HIV infection
13288466,132884661,1,I,,20161128,20170302,20170302,EXP,,US-STRIDES ARCOLAB LIMITED-2016SP020093,STRIDES,"TOUZARD ROMO F, SMEATON LM, CAMPBELL TB, RIVIERE C, MNGQIBISA R, NYIRENDA M, ET AL. RENAL AND METABOLIC TOXICITIES FOLLOWING INITIATION OF HIV-1 TREATMENT REGIMEN IN A DIVERSE, MULTINATIONAL SETTING: A FOCUSED SAFETY ANALYSIS OF ACTG PEARLS (A5175). HIV CLIN TRIALS. 2014;15(6):246-60",,,,,Y,,,20170302,,OT,US,US,EFAVIRENZ,Pancreatitis chronic,132884661,OT,,,,,,,,,132884661,1,HIV infection
13288475,132884751,1,I,,20161128,20170302,20170302,EXP,,US-STRIDES ARCOLAB LIMITED-2016SP020094,STRIDES,"TOUZARD ROMO F, SMEATON LM, CAMPBELL TB, RIVIERE C, MNGQIBISA R, NYIRENDA M, ET AL. RENAL AND METABOLIC TOXICITIES FOLLOWING INITIATION OF HIV-1 TREATMENT REGIMEN IN A DIVERSE, MULTINATIONAL SETTING: A FOCUSED SAFETY ANALYSIS OF ACTG PEARLS (A5175). HIV CLIN TRIALS. 2014;15(6):246-60",,,,,Y,,,20170302,,OT,US,US,EFAVIRENZ,Pancreatitis acute,132884751,OT,,,,,,,,,132884751,1,HIV infection
13288483,132884831,1,I,,20161128,20170302,20170302,EXP,,US-STRIDES ARCOLAB LIMITED-2016SP020096,STRIDES,"TOUZARD ROMO F, SMEATON LM, CAMPBELL TB, RIVIERE C, MNGQIBISA R, NYIRENDA M, ET AL. RENAL AND METABOLIC TOXICITIES FOLLOWING INITIATION OF HIV-1 TREATMENT REGIMEN IN A DIVERSE, MULTINATIONAL SETTING: A FOCUSED SAFETY ANALYSIS OF ACTG PEARLS (A5175). HIV CLIN TRIALS. 2014;15(6):246-60",,,,,Y,,,20170302,,OT,US,US,EFAVIRENZ,Lactic acidosis,132884831,OT,,,,,,,,,132884831,1,HIV infection
13288508,132885081,1,I,,20161128,20170302,20170302,EXP,,US-STRIDES ARCOLAB LIMITED-2016SP020417,STRIDES,"CAMPBELL TB, SMEATON LM, KUMARASAMY N, FLANIGAN T, KLINGMAN KL, ET AL. EFFICACY AND SAFETY OF THREE ANTIRETROVIRAL REGIMENS FOR INITIAL TREATMENT OF HIV-1: A RANDOMIZED CLINICAL TRIAL IN DIVERSE MULTINATIONAL SETTINGS. PLOS MED. 2012;9(8):E1001290",,,,,Y,,,20170302,,OT,US,US,EFAVIRENZ,Virologic failure,132885081,OT,,,,,,,,,132885081,1,HIV infection
13288512,132885121,1,I,,20161128,20170302,20170302,EXP,,US-STRIDES ARCOLAB LIMITED-2016SP020098,STRIDES,"TOUZARD ROMO F, SMEATON LM, CAMPBELL TB, RIVIERE C, MNGQIBISA R, NYIRENDA M, ET AL. RENAL AND METABOLIC TOXICITIES FOLLOWING INITIATION OF HIV-1 TREATMENT REGIMEN IN A DIVERSE, MULTINATIONAL SETTING: A FOCUSED SAFETY ANALYSIS OF ACTG PEARLS (A5175). HIV CLIN TRIALS.. 2014;15(6):246-60",,,,,Y,,,20170302,,OT,US,US,EFAVIRENZ,Body fat disorder,132885121,OT,,,,,,,,,132885121,1,HIV infection
13288522,132885221,1,I,,20161128,20170302,20170302,EXP,,US-STRIDES ARCOLAB LIMITED-2016SP020099,STRIDES,"TOUZARD ROMO F, SMEATON LM, CAMPBELL TB, RIVIERE C, MNGQIBISA R, NYIRENDA M, ET AL. RENAL AND METABOLIC TOXICITIES FOLLOWING INITIATION OF HIV-1 TREATMENT REGIMEN IN A DIVERSE, MULTINATIONAL SETTING: A FOCUSED SAFETY ANALYSIS OF ACTG PEARLS (A5175). HIV CLIN TRIALS. 2014;15(6):246-60",,,,,Y,,,20170302,,OT,US,US,EFAVIRENZ,Body fat disorder,132885221,OT,,,,,,,,,132885221,1,HIV infection
13288545,132885451,1,I,,20161128,20170302,20170302,PER,,US-STRIDES ARCOLAB LIMITED-2016SP020418,STRIDES,"CAMPBELL TB, SMEATON LM, KUMARASAMY N, FLANIGAN T, KLINGMAN KL, ET AL. EFFICACY AND SAFETY OF THREE ANTIRETROVIRAL REGIMENS FOR INITIAL TREATMENT OF HIV-1: A RANDOMIZED CLINICAL TRIAL IN DIVERSE MULTINATIONAL SETTINGS. PLOS MED. 2012;9(8):E1001290",,,,,Y,,,20170302,,OT,US,US,EFAVIRENZ,Exposure during pregnancy,,,,,,,,,,,132885451,1,HIV infection
13289535,132895351,1,I,,20170209,20170303,20170303,EXP,,SG-SUN PHARMACEUTICAL INDUSTRIES LTD-2017RR-134089,RANBAXY,"PHOON YW, CHAN YY, KOH TH. ISOLATION OF MULTIDRUG-RESISTANT SALMONELLA IN SINGAPORE. SINGAPORE-MED-J. 2015;56(8):E142-4",65,YR,,M,Y,,,20170303,,OT,SG,SG,Efavirenz,Drug ineffective;Pathogen resistance,132895351,OT,,,,,,,,,132895351,1,Pneumocystis jirovecii pneumonia
13291602,132916021,1,I,,20170222,20170303,20170303,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2017029870,VIIV,"KIGGUNDU, R., NABETA, H.W., OKIA, R., RHEIN, J., LUKUNDE R. UNMASKING HISTOPLASMOSIS IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN A PATIENT RECENTLY STARTED ON ANTIRETROVIRAL THERAPY.. AUTOPSY + CASE REPORTS. 2016;(4):27-33",43,YR,,M,Y,,,20170303,,OT,UG,UG,EFAVIRENZ,Immune reconstitution inflammatory syndrome,132916021,HO,,,,,,,,,132916021,1,HIV infection
13291885,132918851,1,I,,20170222,20170303,20170303,EXP,,UG-GLAXOSMITHKLINE-UG2017029870,GLAXOSMITHKLINE,"KIGGUNDU, R., NABETA, H.W., OKIA, R., RHEIN, J., LUKUNDE R. UNMASKING HISTOPLASMOSIS IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN A PATIENT RECENTLY STARTED ON ANTIRETROVIRAL THERAPY.. AUTOPSY + CASE REPORTS. 2016;(4):27-33",43,YR,,M,Y,,,20170303,,OT,UG,UG,EFAVIRENZ,Immune reconstitution inflammatory syndrome,132918851,HO,,,,,,,,,132918851,1,HIV infection
13297351,132973511,1,I,20160501,20170228,20170306,20170306,EXP,,CN-GLAXOSMITHKLINE-CN2017GSK030103,GLAXOSMITHKLINE,,55,YR,,M,Y,52,KG,20170306,,OT,CN,CN,EFAVIRENZ,Dermatitis allergic;Flushing;Product use issue;Pruritus;Pyrexia;Rash;Rash maculo-papular,132973511,OT,,,,,,,,,132973511,1,Acquired immunodeficiency syndrome
13299972,132999721,1,I,,20170301,20170306,20170306,EXP,,US-GILEAD-2017-0260918,GILEAD,,48,YR,A,F,Y,,,20170306,,PH,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Renal injury,132999721,OT,,,132999721,1,1999,,,,132999721,1,Product used for unknown indication
13301143,133011431,1,I,,20170223,20170307,20170307,EXP,,TW-CIPLA LTD.-2017TW03310,CIPLA,,,,,,Y,,,20170307,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133011431,OT,,,,,,,,,133011431,1,HIV infection
13301145,133011451,1,I,,20170223,20170307,20170307,EXP,,TW-CIPLA LTD.-2017TW03304,CIPLA,,,,,,Y,,,20170307,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133011451,OT,,,,,,,,,133011451,1,HIV infection
13301155,133011551,1,I,,20170223,20170307,20170307,EXP,,TW-CIPLA LTD.-2017TW03274,CIPLA,,,,,,Y,,,20170307,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133011551,OT,,,,,,,,,133011551,1,HIV infection
13301186,133011861,1,I,,20170223,20170307,20170307,EXP,,TW-CIPLA LTD.-2017TW03368,CIPLA,,,,,,Y,,,20170307,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133011861,OT,,,,,,,,,133011861,1,HIV infection
13301255,133012551,1,I,,20170223,20170307,20170307,EXP,,TW-CIPLA LTD.-2017TW03370,CIPLA,,,,,,Y,,,20170307,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133012551,OT,,,,,,,,,133012551,1,HIV infection
13301593,133015931,1,I,20160501,20170228,20170307,20170307,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2017GSK030103,VIIV,,55,YR,,M,Y,52,KG,20170307,,OT,CN,CN,EFAVIRENZ,Dermatitis allergic;Flushing;Product use issue;Pruritus;Pyrexia;Rash;Rash maculo-papular,133015931,HO,,,,,,,,,133015931,1,Acquired immunodeficiency syndrome
13302567,133025671,1,I,,20170220,20170307,20170307,EXP,,"GB-IMPAX LABORATORIES, INC-2017-IPXL-00490",IMPAX,"YOGANATHAN K, ROBERTS B, HEATLEY MK.. LIFE-THREATENING DIGOXIN TOXICITY DUE TO DRUG???DRUG INTERACTIONS IN AN HIV-POSITIVE MAN. INTERNATIONAL JOURNAL OF STD AND AIDS. 2017;28(3):297-01",51,YR,,M,Y,,,20170307,,OT,GB,GB,EFAVIRENZ,Atrial flutter;Conjunctival pallor;Decreased appetite;Drug interaction;Dyspnoea;HIV infection;Hepatitis B;Nausea;Oral candidiasis;Renal impairment;Toxicity to various agents;Vomiting;Weight decreased,133025671,LT,,,133025671,1,2009,,,,133025671,1,Product used for unknown indication
13303645,133036451,1,I,20170301,20170302,20170307,20170307,EXP,,ZW-GILEAD-2017-0261170,GILEAD,,54,YR,A,M,Y,65.7,KG,20170307,,OT,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia,133036451,HO,,,133036451,1,20140701,20160622,,,133036451,1,Kaposi's sarcoma AIDS related
13304072,133040721,1,I,,20170223,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03338,CIPLA,,,,,,Y,,,20170308,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133040721,OT,,,,,,,,,133040721,1,HIV infection
13304076,133040761,1,I,,20170223,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03704,CIPLA,,,,,,Y,,,20170308,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133040761,OT,,,,,,,,,133040761,1,HIV infection
13304079,133040791,1,I,,20170223,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03703,CIPLA,,,,,,Y,,,20170308,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133040791,OT,,,,,,,,,133040791,1,HIV infection
13304080,133040801,1,I,,20170223,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03279,CIPLA,,,,,,Y,,,20170308,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133040801,OT,,,,,,,,,133040801,1,HIV infection
13304081,133040811,1,I,,20170223,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03677,CIPLA,,,,,,Y,,,20170308,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133040811,OT,,,,,,,,,133040811,1,HIV infection
13304184,133041841,1,I,,20170223,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03743,CIPLA,,,,,,Y,,,20170308,,OT,TW,TW,Efavirenz,Adverse event,133041841,OT,,,,,,,,,133041841,1,HIV infection
13304195,133041951,1,I,,20170223,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03808,CIPLA,,,,,,Y,,,20170308,,OT,TW,TW,Efavirenz,Neuropsychiatric symptoms;Rash,133041951,OT,,,,,,,,,133041951,1,HIV infection
13304258,133042581,1,I,,20170223,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03696,CIPLA,,,,,,Y,,,20170308,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133042581,OT,,,,,,,,,133042581,1,HIV infection
13304259,133042591,1,I,,20170223,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03369,CIPLA,,,,,,Y,,,20170308,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133042591,OT,,,,,,,,,133042591,1,HIV infection
13304265,133042651,1,I,,20170223,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03308,CIPLA,,,,,,Y,,,20170308,,OT,TW,TW,Efavirenz,Alanine aminotransferase increased;Drug resistance;Virologic failure,133042651,OT,,,,,,,,,133042651,1,HIV infection
13304325,133043251,1,I,,20170223,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03711,CIPLA,,,,,,Y,,,20170308,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133043251,OT,,,,,,,,,133043251,1,HIV infection
13304338,133043381,1,I,,20170223,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03819,CIPLA,,,,,,Y,,,20170308,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133043381,OT,,,,,,,,,133043381,1,HIV infection
13304340,133043401,1,I,,20170223,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03834,CIPLA,,,,,,Y,,,20170308,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133043401,OT,,,,,,,,,133043401,1,HIV infection
13304403,133044031,1,I,,20170223,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03315,CIPLA,,,,,,Y,,,20170308,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133044031,OT,,,,,,,,,133044031,1,HIV infection
13304405,133044051,1,I,,20170223,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03689,CIPLA,,,,,,Y,,,20170308,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133044051,OT,,,,,,,,,133044051,1,HIV infection
13304813,133048131,1,I,,20170223,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW02725,CIPLA,,,,,,Y,,,20170308,,OT,TW,TW,Efavirenz,Hyperlipidaemia;Lipodystrophy acquired,133048131,OT,,,,,,,,,133048131,1,HIV infection
13304890,133048901,1,I,,20170223,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03828,CIPLA,,,,,,Y,,,20170308,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133048901,OT,,,,,,,,,133048901,1,HIV infection
13304896,133048961,1,I,,20170223,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03804,CIPLA,,,,,,Y,,,20170308,,OT,TW,TW,Efavirenz,Delirium;Nervous system disorder;Psychotic disorder,133048961,OT,,,,,,,,,133048961,1,HIV infection
13305738,133057382,2,F,,20170301,20170308,20170315,EXP,,FR-ASTELLAS-2017US008609,ASTELLAS,,,,,M,Y,4,KG,20170315,,OT,FR,FR,SUSTIVA,Foetal growth restriction,133057382,OT,,,,,,,,,133057382,1,Product used for unknown indication
13305741,133057411,1,I,,20170301,20170308,20170308,EXP,,FR-ASTELLAS-2017US008617,ASTELLAS,,,,,F,Y,,,20170308,,OT,FR,FR,SUSTIVA,Amniotic fluid volume increased;Exposure during pregnancy;Headache;Hypertension;Metrorrhagia;Premature labour,133057411,HO,,,,,,,,,133057411,1,Product used for unknown indication
13306007,133060071,1,I,,20170223,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW02981,CIPLA,,,,,,Y,,,20170308,,OT,TW,TW,Efavirenz,Alanine aminotransferase increased;Drug resistance;Pyrexia;Rash;Virologic failure,133060071,OT,,,,,,,,,133060071,1,HIV infection
13306008,133060081,1,I,,20170223,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03034,CIPLA,,,,,,Y,,,20170308,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133060081,OT,,,,,,,,,133060081,1,HIV infection
13306184,133061842,2,F,,20170302,20170308,20170310,EXP,,GB-GILEAD-2017-0260923,GILEAD,,,,A,M,Y,,,20170310,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Haemorrhage;Mobility decreased,133061842,HO,,,,,,,,,133061842,1,Product used for unknown indication
13306326,133063261,1,I,,20170223,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03672,CIPLA,,,,,,Y,,,20170308,,OT,TW,TW,Efavirenz,Drug resistance;Nervous system disorder;Virologic failure,133063261,OT,,,,,,,,,133063261,1,HIV infection
13306345,133063451,1,I,,20170223,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03673,CIPLA,,,,,,Y,,,20170308,,OT,TW,TW,Efavirenz,Alanine aminotransferase increased;Aspartate aminotransferase increased;Nephropathy toxic,133063451,OT,,,,,,,,,133063451,1,HIV infection
13306364,133063641,1,I,,20170223,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03675,CIPLA,,,,,,Y,,,20170308,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133063641,OT,,,,,,,,,133063641,1,HIV infection
13306410,133064101,1,I,,20170223,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03679,CIPLA,,,,,,Y,,,20170308,,OT,TW,TW,Efavirenz,Drug resistance;Rash;Virologic failure,133064101,OT,,,,,,,,,133064101,1,HIV infection
13306421,133064211,1,I,,20170223,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03676,CIPLA,,,,,,Y,,,20170308,,OT,TW,TW,Efavirenz,Drug resistance;Nervous system disorder;Virologic failure,133064211,OT,,,,,,,,,133064211,1,HIV infection
13306443,133064431,1,I,,20170227,20170308,20170308,EXP,,AR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-020346,BRISTOL MYERS SQUIBB,,75,YR,,M,Y,,,20170308,,OT,AR,AR,EFAVIRENZ,Herbal interaction;Viral load increased,133064431,OT,,,133064431,1,2007,,,,133064431,1,HIV infection
13306444,133064442,2,F,201303,20170315,20170308,20170323,EXP,,AR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-019946,BRISTOL MYERS SQUIBB,,47,YR,,F,Y,67,KG,20170323,,OT,AR,AR,EFAVIRENZ,Herbal interaction;Viral load increased,133064442,OT,,,133064442,1,2007,,,,133064442,1,HIV infection
13312734,133127341,1,I,20160519,20170307,20170308,20170308,EXP,,BR-GILEAD-2017-0261525,GILEAD,,52,YR,A,M,Y,79,KG,20170308,,MD,BR,BR,EFAVIRENZ,Acute myocardial infarction,133127341,HO,,,133127341,1,20131114,,,,133127341,1,HIV infection
13313903,133139031,1,I,,20170306,20170309,20170309,EXP,,US-GILEAD-2017-0261559,GILEAD,,,,,M,Y,,,20170309,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Autoimmune hepatitis;Liver disorder,133139031,OT,,,,,,,,,133139031,1,Product used for unknown indication
13314596,133145961,1,I,20170302,20170302,20170309,20170309,EXP,,BR-ABBVIE-17P-020-1899514-00,ABBVIE,,,,,M,Y,70,KG,20170309,,CN,BR,BR,EFAVIRENZ,CD4 lymphocytes decreased;Incorrect dose administered;Intracranial mass;Mental disorder;Schizophrenia;Suicidal ideation,133145961,OT,,,,,,,,,133145961,1,HIV infection
13319496,133194961,1,I,,20170223,20170309,20170309,EXP,,TW-CIPLA LTD.-2017TW03714,CIPLA,,,,,,Y,,,20170309,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133194961,OT,,,,,,,,,133194961,1,HIV infection
13319534,133195341,1,I,,20170223,20170309,20170309,EXP,,TW-CIPLA LTD.-2017TW03682,CIPLA,,,,,,Y,,,20170309,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133195341,OT,,,,,,,,,133195341,1,HIV infection
13319579,133195791,1,I,,20170223,20170309,20170309,EXP,,TW-CIPLA LTD.-2017TW03721,CIPLA,,,,,,Y,,,20170309,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133195791,OT,,,,,,,,,133195791,1,HIV infection
13319615,133196151,1,I,,20170223,20170309,20170309,EXP,,TW-CIPLA LTD.-2017TW03710,CIPLA,,,,,,Y,,,20170309,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133196151,OT,,,,,,,,,133196151,1,HIV infection
13319695,133196951,1,I,,20170223,20170309,20170309,EXP,,TW-CIPLA LTD.-2017TW03906,CIPLA,,,,,,Y,,,20170309,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133196951,OT,,,,,,,,,133196951,1,HIV infection
13319736,133197361,1,I,,20170223,20170309,20170309,EXP,,TW-CIPLA LTD.-2017TW03429,CIPLA,,,,,,Y,,,20170309,,OT,TW,TW,Efavirenz,Adverse event,133197361,OT,,,,,,,,,133197361,1,HIV infection
13319748,133197481,1,I,,20170223,20170309,20170309,EXP,,TW-CIPLA LTD.-2017TW03782,CIPLA,,,,,,Y,,,20170309,,OT,TW,TW,Efavirenz,Dizziness;Drug resistance;Insomnia;Nervous system disorder;Virologic failure,133197481,OT,,,,,,,,,133197481,1,HIV infection
13319753,133197531,1,I,,20170223,20170309,20170309,EXP,,TW-CIPLA LTD.-2017TW03850,CIPLA,,,,,,Y,,,20170309,,OT,TW,TW,Efavirenz,Completed suicide;Rash,133197531,DE,,,,,,,,,133197531,1,HIV infection
13319758,133197581,1,I,,20170223,20170309,20170309,EXP,,TW-CIPLA LTD.-2017TW03795,CIPLA,,,,,,Y,,,20170309,,OT,TW,TW,Efavirenz,Drug resistance;Virologic failure,133197581,OT,,,,,,,,,133197581,1,HIV infection
13325639,133256391,1,I,,20170223,20170308,20170308,EXP,,TW-CIPLA LTD.-2017TW03829,CIPLA,,,,,,Y,,,20170309,,OT,TW,TW,Efavirenz,Renal impairment,133256391,OT,,,,,,,,,133256391,1,HIV infection
13329609,133296091,1,I,20140928,20170301,20170313,20170313,EXP,FR-AFSSAPS-PO20170216,FR-GLAXOSMITHKLINE-FR2017GSK031098,GLAXOSMITHKLINE,,37,YR,,F,Y,,,20170313,,OT,FR,FR,SUSTIVA,Exposure during pregnancy;Foetal growth restriction,133296091,OT,,,,,,,,,133296091,1,Product used for unknown indication
13333009,133330091,1,I,201612,20170227,20170313,20170313,EXP,,ZA-TEVA-748657ISR,TEVA,,27,YR,,F,Y,70,KG,20170313,,MD,ZA,ZA,efavirenz,Burning sensation;Diarrhoea;Drug reaction with eosinophilia and systemic symptoms;Eosinophil count increased;Gastroenteritis;Liver function test abnormal;Neutropenia;Pyrexia;Rash generalised;Rash macular;Rash vesicular;Skin reaction;Tachycardia;Vomiting;Vulvovaginal pruritus;White blood cell count decreased,133330091,HO,,,133330091,1,20161213,20161219,,,133330091,1,Tuberculosis
13333385,133333851,1,I,20140928,20170301,20170313,20170313,EXP,FR-AFSSAPS-PO20170216,FR-VIIV HEALTHCARE LIMITED-FR2017GSK031098,VIIV,,37,YR,,F,Y,,,20170313,,OT,FR,FR,SUSTIVA,Exposure during pregnancy;Foetal growth restriction,133333851,OT,,,,,,,,,133333851,1,Product used for unknown indication
13335529,133355291,1,I,,20170303,20170315,20170315,EXP,,BR-HETERO LABS LTD-1064248,HETERO,,,,,M,Y,,,20170315,,OT,BR,BR,Efavirenz\ lamivudine \ Tenofovir  disoproxil fumarate,Congenital naevus;Foetal exposure during pregnancy,133355291,CA,,,,,,,,,133355291,1,HIV infection
13335634,133356341,1,I,,20170309,20170314,20170314,EXP,,US-GILEAD-2017-0262293,GILEAD,,56,YR,A,M,Y,,,20170314,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Affective disorder;Anxiety disorder;Bipolar disorder,133356341,OT,,,133356341,1,2009,,,,133356341,1,HIV infection
13335985,133359851,1,I,20150430,20170301,20170314,20170314,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-021688,BRISTOL MYERS SQUIBB,,37,YR,,F,Y,,,20170314,,CN,FR,FR,SUSTIVA,Gestational hypertension;Headache;Live birth;Maternal exposure during pregnancy;Metrorrhagia;Placental disorder;Premature labour;Product use issue;Streptococcus test positive,133359851,OT,,,,,,,,,133359851,1,Product used for unknown indication
13335986,133359861,1,I,20150224,20170301,20170314,20170314,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-018934,BRISTOL MYERS SQUIBB,,0,YR,,M,Y,2.64,KG,20170314,,CN,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Foetal growth restriction,133359861,OT,,,,,,,,,133359861,1,Product used for unknown indication
13339610,133396101,1,I,,20170310,20170315,20170315,EXP,,US-GILEAD-2017-0262237,GILEAD,,51,YR,A,M,Y,,,20170315,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Neoplasm malignant,133396101,OT,,,,,,,,,133396101,1,HIV infection
13339761,133397611,1,I,,20170215,20170315,20170315,EXP,,FR-009507513-1702FRA008692,MERCK,,28,YR,,F,Y,,,20170315,,CN,US,FR,EFAVIRENZ,Abortion induced;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue,133397611,OT,,,133397611,1,201110,,,,133397611,1,HIV infection
13343354,133433541,1,I,,20170307,20170316,20170316,EXP,,ZA-MYLANLABS-2017M1016192,MYLAN,"PINILLOS F, DANDARA C, SWART M, STREHLAU R, KUHN L, PATEL F, ET AL. CASE REPORT: SEVERE CENTRAL NERVOUS SYSTEM MANIFESTATIONS ASSOCIATED WITH ABERRANT EFAVIRENZ METABOLISM IN CHILDREN: THE ROLE OF CYP2B6 GENETIC VARIATION. BMC-INFECT-DIS 2016;16:56.",,,,,Y,,,20170316,,OT,ZA,ZA,EFAVIRENZ,Nervous system disorder,133433541,HO,,,,,,,,,133433541,1,Perinatal HIV infection
13343835,133438351,1,I,,20170307,20170316,20170316,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-023107,BRISTOL MYERS SQUIBB,,7,YR,,F,Y,,,20170316,,OT,US,ZA,EFAVIRENZ,Generalised tonic-clonic seizure,133438351,OT,,,,,,,,,133438351,1,Antiretroviral therapy
13343839,133438391,1,I,,20170307,20170316,20170316,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-023108,BRISTOL MYERS SQUIBB,,4,YR,,F,Y,,,20170316,,OT,US,ZA,EFAVIRENZ,Petit mal epilepsy,133438391,OT,,,,,,,,,133438391,1,Antiretroviral therapy
13349412,133494121,1,I,,20170311,20170320,20170320,EXP,,BR-STRIDES ARCOLAB LIMITED-2017SP004518,STRIDES,,,,,,Y,,,20170320,,OT,BR,BR,EFAVIRENZ W/LAMIVUDINE/TENOFOVIR DISOPROXIL F,Congenital naevus;Foetal exposure during pregnancy,133494121,CA,,,133494121,2,20170302,20170302,,,133494121,1,Product used for unknown indication
13350010,133500101,1,I,,20170308,20170320,20170320,EXP,,CN-MYLANLABS-2017M1017020,MYLAN,"ZUO S, XU N, LI Z, LI N, XIA H, REN H, ET AL. CLINICAL ANALYSIS OF FIVE CASES OF AIDS-RELATED NON-HODGKIN LYMPHOMA. PAK-J-MED-SCI 2016;32(6):1574-1579.",,,,,Y,,,20170320,,MD,CN,CN,EFAVIRENZ,Bone marrow failure;Gastrointestinal disorder,133500101,OT,,,,,,,,,133500101,1,Acquired immunodeficiency syndrome
13350473,133504731,1,I,,20170308,20170320,20170320,EXP,,CN-MYLANLABS-2017M1017177,MYLAN,"ZUO S, XU N, LI Z, LI N, XIA H, REN H, ET AL. CLINICAL ANALYSIS OF FIVE CASES OF AIDS-RELATED NON-HODGKIN LYMPHOMA. PAK-J-MED-SCI 2016;32(6):1574-1579.",,,,,Y,,,20170320,,MD,CN,CN,EFAVIRENZ,Acinetobacter infection;Bone marrow failure;Gastrointestinal disorder;Respiratory failure;Sepsis,133504731,DE,,,,,,,,,133504731,1,Acquired immunodeficiency syndrome
13350474,133504741,1,I,,20170308,20170320,20170320,EXP,,CN-MYLANLABS-2017M1017180,MYLAN,"ZUO S, XU N, LI Z, LI N, XIA H, REN H, ET AL. CLINICAL ANALYSIS OF FIVE CASES OF AIDS-RELATED NON-HODGKIN LYMPHOMA. PAK-J-MED-SCI 2016;32(6):1574-1579.",,,,,Y,,,20170320,,MD,CN,CN,EFAVIRENZ,Bone marrow failure;Gastrointestinal disorder,133504741,OT,,,,,,,,,133504741,1,Acquired immunodeficiency syndrome
13353790,133537901,1,I,,20170308,20170321,20170321,EXP,,US-CIPLA LTD.-2017US04544,CIPLA,,,,,,Y,,,20170321,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Viral load increased,133537901,OT,,,,,,,,,133537901,1,HIV infection
13353796,133537961,1,I,,20170308,20170321,20170321,EXP,,US-CIPLA LTD.-2017US04546,CIPLA,,,,,,Y,,,20170321,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Viral load increased,133537961,OT,,,,,,,,,133537961,1,HIV infection
13357112,133571121,1,I,,20170308,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04548,CIPLA,,,,,,Y,,,20170322,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Viral load increased,133571121,OT,,,,,,,,,133571121,1,HIV infection
13357116,133571161,1,I,,20170308,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04547,CIPLA,,,,,,Y,,,20170322,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Viral load increased,133571161,OT,,,,,,,,,133571161,1,HIV infection
13357117,133571171,1,I,,20170308,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04558,CIPLA,,,,,,Y,,,20170322,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Virologic failure,133571171,OT,,,,,,,,,133571171,1,HIV infection
13357206,133572061,1,I,,20170308,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04554,CIPLA,,,,,,Y,,,20170322,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Road traffic accident,133572061,OT,,,,,,,,,133572061,1,HIV infection
13357456,133574561,1,I,,20170308,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04553,CIPLA,,,,,,Y,,,20170322,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Ulcer haemorrhage,133574561,OT,,,,,,,,,133574561,1,HIV infection
13357463,133574631,1,I,,20170308,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04556,CIPLA,,,,,,Y,,,20170322,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Drug resistance;Virologic failure,133574631,OT,,,,,,,,,133574631,1,HIV infection
13358135,133581351,1,I,,20170308,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04538,CIPLA,,,,,,Y,,,20170322,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Viral load increased,133581351,OT,,,,,,,,,133581351,1,HIV infection
13358154,133581541,1,I,,20170308,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04571,CIPLA,,,,,,Y,,,20170322,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Virologic failure,133581541,OT,,,,,,,,,133581541,1,HIV infection
13358186,133581861,1,I,,20170308,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04569,CIPLA,,,,,,Y,,,20170322,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Virologic failure,133581861,OT,,,,,,,,,133581861,1,HIV infection
13358189,133581891,1,I,,20170308,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04570,CIPLA,,,,,,Y,,,20170322,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Virologic failure,133581891,OT,,,,,,,,,133581891,1,HIV infection
13358201,133582011,1,I,,20170308,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04567,CIPLA,,,,,,Y,,,20170322,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Virologic failure,133582011,OT,,,,,,,,,133582011,1,HIV infection
13358208,133582081,1,I,,20170308,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04568,CIPLA,,,,,,Y,,,20170322,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Virologic failure,133582081,OT,,,,,,,,,133582081,1,HIV infection
13358215,133582151,1,I,,20170308,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04563,CIPLA,,,,,,Y,,,20170322,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Virologic failure,133582151,OT,,,,,,,,,133582151,1,HIV infection
13358220,133582201,1,I,,20170308,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04549,CIPLA,,,,,,Y,,,20170322,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Death,133582201,DE,,,,,,,,,133582201,1,HIV infection
13358238,133582381,1,I,,20170308,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04542,CIPLA,,,,,,Y,,,20170322,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Viral load increased,133582381,OT,,,,,,,,,133582381,1,HIV infection
13358250,133582501,1,I,,20170308,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04540,CIPLA,,,,,,Y,,,20170322,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Viral load increased,133582501,OT,,,,,,,,,133582501,1,HIV infection
13358261,133582611,1,I,,20170308,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04539,CIPLA,,,,,,Y,,,20170322,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Viral load increased,133582611,OT,,,,,,,,,133582611,1,HIV infection
13358280,133582801,1,I,,20170308,20170322,20170322,EXP,,US-CIPLA LTD.-2017US04537,CIPLA,,,,,,Y,,,20170322,,OT,US,US,Tenofovir/Emtricitabine/Efavirenz,Viral load increased,133582801,OT,,,,,,,,,133582801,1,HIV infection
13360010,133600101,1,I,20170126,20170314,20170322,20170322,EXP,,CD-JNJFOC-20170317513,JANSSEN,,40,YR,A,F,Y,,,20170322,,OT,CD,CD,EFAVIRENZ,Abdominal distension;Abdominal pain;Anaemia;Hypovolaemic shock;Psychotic disorder;Respiratory disorder;Sepsis,133600101,DE,,,133600101,2,20161207,,,,133600101,1,Tuberculosis
13360371,133603711,1,I,20170125,20170314,20170322,20170322,EXP,,CD-JNJFOC-20170317491,JANSSEN,,48,YR,A,F,Y,,,20170322,,OT,CD,CD,EFAVIRENZ,Asthenia;Candida infection;Diarrhoea;Electrolyte imbalance;Genital ulceration;Hypotension;Melaena;Oedema peripheral;Oral herpes;Swelling face;Vertigo;Vomiting,133603711,DE,,,133603711,1,20161228,,,,133603711,1,Tuberculosis
13361439,133614391,1,I,20160701,20170307,20170323,20170323,EXP,,SE-GILEAD-2017-0262105,GILEAD,,72,YR,E,M,Y,,,20170322,,MD,SE,SE,EFAVIRENZ,Pruritus;Rash,133614391,OT,,,133614391,1,20160623,20170112,,,133614391,1,Product used for unknown indication
13368899,133688991,1,I,2014,20170316,20170324,20170324,EXP,,CO-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-024639,BRISTOL MYERS SQUIBB,,46,YR,,M,Y,75,KG,20170324,,OT,CO,CO,EFAVIRENZ,Dyspnoea;Post procedural sepsis;Sleep disorder;Somnolence;Turbinectomy,133688991,HO,,,133688991,1,20120101,,,,133688991,1,HIV infection
13372497,133724971,1,I,,20160408,20170327,20170327,EXP,,GB-HETERO LABS LTD-1064662,HETERO,,,,,M,Y,,,20170327,,OT,GB,GB,Efavirenz,Sleep disorder,133724971,OT,,,,,,,,,133724971,1,Product used for unknown indication
13378144,133781441,1,I,2015,20170321,20170328,20170328,EXP,,US-GILEAD-2017-0263920,GILEAD,,44,YR,A,M,Y,,,20170328,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hodgkin's disease stage IV;Neuropathy peripheral,133781441,OT,,,133781441,1,201001,201612,,,133781441,1,HIV infection
13385618,133856181,1,I,,20170320,20170330,20170330,EXP,,CN-FRESENIUS KABI-FK201702635,FRESENIUS KABI,"ZUO S,XU N,LI Z,LI N,XIA H,REN H. CLINICAL ANALYSIS OF FIVE CASES OF AIDS-RELATED NON-HODGKIN LYMPHOMA. PAK-J-MED-SCI 2016;32(6):1574-1579.",28,YR,,M,Y,,,20170330,,OT,CN,CN,EFAVIRENZ,Bone marrow failure;Gastrointestinal disorder;Respiratory failure;Sepsis,133856181,OT,,,,,,,,,133856181,1,Non-Hodgkin's lymphoma
13387568,133875681,1,I,,20170323,20170330,20170330,EXP,,GE-009507513-1703GEO011957,MERCK,,38,YR,,M,Y,,,20170330,,OT,GE,GE,EFAVIRENZ,Pulmonary tuberculosis,133875681,OT,,,,,,,,,133875681,1,Hepatitis C
13388567,133885671,1,I,,20170321,20170330,20170330,EXP,,BR-ABBVIE-17K-020-1920058-00,ABBVIE,,,,,M,Y,73,KG,20170330,,CN,BR,BR,EFAVIRENZ,Blindness unilateral;Cerebrovascular accident;Crying;Dysphonia;Eye contusion;Eye disorder;Gait disturbance;HIV infection;Immunodeficiency;Liver disorder;Malaise;Meningitis;Panic reaction;Retinopathy;Schizophrenia;Syphilis;Ulcer;Unevaluable event;Urinary tract infection;Visual acuity reduced;Visual impairment,133885671,OT,,,133885671,1,201604,,,,133885671,1,HIV infection
13389042,133890421,1,I,,20170324,20170330,20170330,EXP,,"GE-KADMON PHARMACEUTICALS, LLC-KAD201703-000588",KADMON,"ABUTIDZE A,BOLOKADZE N,CHKHARTISHVILI N,SHARVADZE L,TSERTSVADZE T. INCIDENCE OF TUBERCULOSIS AMONG HIV/HCV COINFECTED PATIENTS RECEIVING HEPATITIS C TREATMENT WITH PEGYLATED INTERFERON AND RIBAVIRIN IN GEORGIA. GEORGIAN MED NEWS 2016 MAR;252:10-5.",38,YR,,M,Y,,,20170330,,OT,GE,GE,Tenofovir/Emtricitabine/Efavirenz,Pulmonary tuberculosis,133890421,OT,,,,,,,,,133890421,1,Hepatitis C
13389140,133891401,1,I,,20170324,20170330,20170330,EXP,,"GE-KADMON PHARMACEUTICALS, LLC-KAD201703-000591",KADMON,"ABUTIDZE A,BOLOKADZE N,CHKHARTISHVILI N,SHARVADZE L,TSERTSVADZE T. INCIDENCE OF TUBERCULOSIS AMONG HIV/HCV CO-INFECTED PATIENTS RECEIVING HEPATITIS C TREATMENT WITH PEGYLATED INTERFERON AND RIBAVIRIN IN GEORGIA. GEORGIAN MED NEWS 2016 MAR;252:10-15.",30,YR,,M,Y,,,20170330,,OT,GE,GE,Tenofovir/Emtricitabine/Efavirenz,Drug effect incomplete;Pulmonary tuberculosis,133891401,OT,,,,,,,,,133891401,1,Hepatitis C
13392626,133926261,1,I,,20170323,20170331,20170331,EXP,,GE-009507513-1703GEO012521,MERCK,,30,YR,,M,Y,,,20170331,,OT,GE,GE,EFAVIRENZ,Pulmonary tuberculosis,133926261,OT,,,,,,,,,133926261,1,Hepatitis C
13392867,133928671,1,I,,20170323,20170331,20170331,EXP,,GE-009507513-1703GEO012522,MERCK,,40,YR,,M,Y,,,20170331,,OT,GE,GE,EFAVIRENZ,Lymph node tuberculosis,133928671,OT,,,,,,,,,133928671,1,Hepatitis C
13392977,133929771,1,I,,20170323,20170331,20170331,EXP,,GE-009507513-1703GEO012523,MERCK,,39,YR,,M,Y,,,20170331,,OT,GE,GE,EFAVIRENZ,Pulmonary tuberculosis,133929771,OT,,,,,,,,,133929771,1,Hepatitis C
13393468,133934681,1,I,,20170324,20170331,20170331,EXP,,"GE-KADMON PHARMACEUTICALS, LLC-KAD201703-000592",KADMON,"ABUTIDZE A,BOLOKADZE N,CHKHARTISHVILI N,SHARVADZE L,TSERTSVADZE T. INCIDENCE OF TUBERCULOSIS AMONG HIV/HCV CO-INFECTED PATIENTS RECEIVING HEPATITIS C TREATMENT WITH PEGYLATED INTERFERON AND RIBAVIRIN IN GEORGIA. GEORGIAN MED NEWS 2016 MAR;252:10-15.",40,YR,,M,Y,,,20170331,,OT,GE,GE,Abacavir/Lamivudine/Efavirenz,Lymph node tuberculosis,133934681,OT,,,,,,,,,133934681,1,Hepatitis C
13393475,133934751,1,I,,20170324,20170331,20170331,EXP,,"GE-KADMON PHARMACEUTICALS, LLC-KAD201703-000593",KADMON,"ABUTIDZE A,BOLOKADZE N,CHKHARTISHVILI N,SHARVADZE L,TSERTSVADZE T. INCIDENCE OF TUBERCULOSIS AMONG HIV/HCV COINFECTED PATIENTS RECEIVING HEPATITIS C TREATMENT WITH PEGYLATED INTERFERON AND RIBAVIRIN IN GEORGIA. GEORGIAN MED NEWS 2016 MAR;252:10-5.",39,YR,,M,Y,,,20170331,,OT,GE,GE,Tenofovir/Emtricitabine/Efavirenz,Pulmonary tuberculosis,133934751,OT,,,,,,,,,133934751,1,Hepatitis C
3998162,39981628,8,F,20030104,20070622,20030915,20170210,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-12374377,BRISTOL MYERS SQUIBB,,47,YR,,M,Y,,,20170210,,OT,JP,JP,EFAVIRENZ,Cerebellar haemorrhage;Hepatic encephalopathy;Hyperammonaemia;Hypertension;Spinal compression fracture,39981628,LT,,,39981628,1,20010906,20040704,,,39981628,1,HIV infection
4102949,41029493,3,F,20040208,20040302,20040309,20170210,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-12524641,BRISTOL MYERS SQUIBB,,33,YR,,M,Y,,,20170210,,CN,US,JP,EFAVIRENZ,Death;Influenza;Pneumococcal sepsis;Pneumonia pneumococcal;Rash;Septic shock,41029493,HO,,,41029493,1,20040123,20040210,,,41029493,1,HIV infection
5679262,56792624,4,F,20030421,20050526,20041122,20170206,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-12768867,BRISTOL MYERS SQUIBB,,50,YR,,M,Y,,,20170206,,CN,US,JP,EFAVIRENZ,Diabetes mellitus,56792624,OT,,,56792624,1,20021217,20040524,,,56792624,1,HIV infection
6091962,60919625,5,F,20050217,20060919,20060727,20170220,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-13442793,BRISTOL MYERS SQUIBB,,46,YR,,M,Y,,,20170220,,CN,US,JP,EFAVIRENZ,Acquired immunodeficiency syndrome;Atrial fibrillation;Cerebral haemorrhage;Coma;Hepatic cirrhosis;Hepatic encephalopathy;Hepatic failure;Jaundice;Lymphoma;Malignant neoplasm progression;Pancytopenia;Platelet count decreased;Renal impairment;Somnolence;White blood cell count decreased,60919625,OT,,,60919625,1,20050202,2005,,,60919625,1,Lymphoma
6146531,61465315,5,F,20040929,20070328,20061013,20170210,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-13533260,BRISTOL MYERS SQUIBB,,33,YR,,M,Y,,,20170210,,CN,US,JP,EFAVIRENZ,Glucose tolerance impaired,61465315,OT,,,61465315,1,20040913,20050404,,,61465315,1,HIV infection
7302622,730262227,27,F,,20170120,20100302,20170124,EXP,,CA-MERCK-0907CAN00093,MERCK,,52,YR,,M,Y,,,20170124,,CN,US,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,730262227,OT,,,730262227,6,200802,,,,730262227,1,HIV infection
8096421,80964213,3,F,,20110929,20110818,20170323,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-15952914,BRISTOL MYERS SQUIBB,,42,YR,,M,Y,,,20170323,,CN,JP,JP,EFAVIRENZ,Drug resistance;Psychiatric symptom,80964213,OT,,,,,,,,,80964213,1,Antiretroviral therapy
